var title_f4_49_4880="Types of stenosis";
var content_f4_49_4880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Different types of tracheal stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    a) segmental stenosis, b) funnel stenosis, c) generalized stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4880=[""].join("\n");
var outline_f4_49_4880=null;
var title_f4_49_4881="Doxofylline: International drug information";
var content_f4_49_4881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxofylline: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4324022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ansimar (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bronchodilator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Theophylline Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptoms and reversible airway obstruction due to chronic asthma, chronic bronchitis, or COPD",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 400 mg 2-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule: 400 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10372 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-063D528ED5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4881=[""].join("\n");
var outline_f4_49_4881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4324022\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978613\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978616\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978612\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821177\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978615\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10372\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10372|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_49_4882="Optic disc Frisen grade 1";
var content_f4_49_4882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc Fris&eacute;n Grade I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fris&eacute;n Grade I showing the C-shaped halo of disc edema with a temporal gap.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4882=[""].join("\n");
var outline_f4_49_4882=null;
var title_f4_49_4883="Femoral intraosseous site";
var content_f4_49_4883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Femoral intraosseous access site",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 526px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Entry site at the distal femur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hodge Dee III. Intraosseous infusion. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4883=[""].join("\n");
var outline_f4_49_4883=null;
var title_f4_49_4884="Bowel resection and reapprox A";
var content_f4_49_4884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Approximation of posterior seromuscular layer during bowel resection and reanastomosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4884=[""].join("\n");
var outline_f4_49_4884=null;
var title_f4_49_4885="Sargramostim: Pediatric drug information";
var content_f4_49_4885=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sargramostim: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/43/5814?source=see_link\">",
"    see \"Sargramostim: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/6/25700?source=see_link\">",
"    see \"Sargramostim: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Leukine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Leukine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Colony-Stimulating Factor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V., SubQ: 10 mcg/kg/dose once daily for 5 days. The PROGRAMS trial (single-blind, multicenter) evaluated use in 280 premature neonates (GA: &le;31 weeks; weight: &le;10th percentile body weight) and showed correction of neutropenia but no reduction in sepsis or improved survival (Carr, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/43/5814?source=see_link\">",
"      see \"Sargramostim: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 250 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily for 21 days to begin 2-4 hours after the marrow infusion on day 0 of BMT or not less than 24 hours after chemotherapy. If significant adverse effects or &ldquo;first dose&rdquo; reaction is seen at this dose, discontinue the drug until toxicity resolves, then restart at a reduced dose of 125 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 250 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily for 21 days to begin 2-4 hours after BMT, or not less than 24 hours after chemotherapy (to minimize first dose reaction, start with low doses and increase gradually)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leukine&reg;: 250 mcg [contains sucrose 10 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leukine&reg;: 500 mcg/mL (1 mL) [contains benzyl alcohol, sucrose 10 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer as a 30-minute, 2-hour, or 6-hour I.V. infusion or by continuous I.V. infusion. Do not shake solution to avoid foaming. Dilute in NS; if the final concentration of GM-CSF in NS is &lt;10 mcg/mL, then add 1 mg albumin per mL of I.V. fluid. Albumin acts as a carrier molecule to prevent drug adsorption to the I.V. tubing. Albumin should be added to NS prior to addition of GM-CSF. An in-line membrane filter should",
"     <b>",
"      not",
"     </b>",
"     be used for intravenous administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ: Reconstituted 250 mcg/mL or 500 mcg/mL solution may be administered without further dilution; rotate injection sites",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F220062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, sterile water for injection, bacteriostatic water;",
"     <b>",
"      incompatible",
"     </b>",
"     with dextrose-containing solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, aminophylline, aztreonam, bleomycin, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefepime, cefotaxime, cefotetan, cefuroxime, cimetidine, cisplatin, clindamycin, cyclophosphamide, cyclosporine, cytarabine, dacarbazine, dactinomycin, dexamethasone sodium phosphate, diphenhydramine, dopamine, doxorubicin, doxycycline, droperidol, etoposide, famotidine, fentanyl, floxuridine, fluconazole, fluorouracil, furosemide, gentamicin, granisetron, heparin, ifosfamide, immune globulin, magnesium sulfate, mannitol, mechlorethamine, meperidine, mesna, methotrexate, metoclopramide, metronidazole, minocycline, mitoxantrone, pentostatin, piperacillin/tazobactam, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, teniposide, ticarcillin/clavulanate, trimethoprim/sulfamethoxazole, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, ampicillin, ampicillin/sulbactam, chlorpromazine, haloperidol, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, lorazepam, methylprednisolone sodium succinate, mitomycin, morphine, nalbuphine, ondansetron, piperacillin, sodium bicarbonate, tobramycin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amphotericin B, amsacrine, ceftazidime, ceftriaxone, ganciclovir, idarubicin, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store vial in the refrigerator; stable after reconstitution for 6 hours at room temperature; use only NS to prepare I.V. infusion solution; GM-CSF at a concentration &ge;10 mcg/mL is compatible with TPN during Y-site administration",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Accelerates myeloid recovery in patients undergoing autologous or allogeneic BMT; mobilize hematopoietic progenitor cells into peripheral blood for collection by leukapheresis; accelerate myeloid engraftment following autologous peripheral blood progenitor cell transplantation; increase neutrophil counts in patients with malignancies receiving myelosuppressive chemotherapy; neonatal neutropenia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Leukine&reg; may be confused with Leukeran&reg;, leucovorin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F220061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, hypertension, pericardial effusion, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, fever, headache, insomnia, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia, hyperglycemia, hypomagnesemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, dysphagia, gastrointestinal hemorrhage, hematemesis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, bone pain, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Eye hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, epistaxis, pharyngitis, pleural effusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Antibody formation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, anaphylaxis, arrhythmia, capillary leak syndrome, constipation, dizziness, eosinophilia; first-dose effect (syndrome with respiratory distress, hypoxia, flushing, hypotension, syncope, and/or tachycardia occurring with the first dose of a treatment cycle); injection site reaction, lethargy, leukocytosis, liver function abnormalities (transient),  pain, pericarditis, prothrombin time prolonged, rigors, sore throat, supraventricular arrhythmia (transient), thrombocytosis, thrombophlebitis, thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to GM-CSF, yeast-derived products, or any component; excessive leukemic myeloid blasts in bone marrow or peripheral blood &ge;10%; history of idiopathic thrombocytopenic purpura",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with autoimmune or chronic inflammatory disease, hypertension, cardiovascular disease, pulmonary disease, or renal or hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Rapid increase in peripheral blood counts: If ANC is &gt;20,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &gt;500,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , decrease dose by 50% or discontinue drug (counts will fall to normal within 3-7 days after discontinuing drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Growth factor potential: Caution with myeloid malignancies; do",
"     <b>",
"      not",
"     </b>",
"     administer within 24 hours prior to or after chemotherapy or 12 hours prior to or after radiation therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection solution contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use sargramostim injection products containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bleomycin: Sargramostim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical effects to the fetus: Animal reproduction studies have not been conducted. It is not known whether sargramostim can cause fetal harm when administered to a pregnant woman or can affect reproductive capability. Sargramostim should be given to a pregnant woman only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelets; renal/liver function tests, especially with previous dysfunction; vital signs, weight; pulmonary function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1049813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excessive leukocytosis (WBC &gt;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ANC &gt;20,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates proliferation, differentiation and functional activity of neutrophils, eosinophils, monocytes and macrophages",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1049817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Increase in WBC in 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: WBC will return to baseline within 1 week after discontinuing drug",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: SubQ: Within 3 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/6/25700?source=see_link\">",
"      see \"Sargramostim: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Possible bone pain may occur",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produced by recombinant DNA technology using a yeast-derived expression system",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Carr R, Brocklehurst P, Dor&eacute; CJ, et al, \"Granulocyte-Macrophage Colony Stimulating Factor Administered as Prophylaxis for Reduction of Sepsis in Extremely Preterm, Small for Gestational Age Neonates (the PROGRAMS Trial): A Single-Blind, Multicentre, Randomised Controlled Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 373(9659):226-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4885/abstract-text/19150703/pubmed\" id=\"19150703\" target=\"_blank\">",
"        19150703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carr R, Modi N, Dore CJ, et al, &ldquo;A Randomized, Controlled Trial of Prophylactic Granulocyte-Macrophage Colony-Stimulating Factor in Human Newborns Less Than 32 Weeks Gestation,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 103(4 Pt 1):796-802.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4885/abstract-text/10103305/pubmed\" id=\"10103305\" target=\"_blank\">",
"        10103305",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lieschke GJ and Burgess AW, &ldquo;Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor,&rdquo; (1)",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(1):28-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4885/abstract-text/1375975/pubmed\" id=\"1375975\" target=\"_blank\">",
"        1375975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lieschke GJ and Burgess AW, &ldquo;Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor,&rdquo; (2)",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(2):99-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4885/abstract-text/1376442/pubmed\" id=\"1376442\" target=\"_blank\">",
"        1376442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stute N, Furman WL, Schell M, et al, &ldquo;Pharmacokinetics of Recombinant Human Granulocyte - Macrophage Colony - Stimulating Factor in Children After Intravenous and Subcutaneous Administration,&rdquo;",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1995, 84(7):824-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4885/abstract-text/7562431/pubmed\" id=\"7562431\" target=\"_blank\">",
"        7562431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA, Bready BB, Kwan JW, et al, &ldquo;Visual Compatibility of Sargramostim With Selected Antineoplastic Agents, Anti-infectives, or Other Drugs During Simulated Y-Site Injection,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1992, 49(2):402-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4885/abstract-text/1554007/pubmed\" id=\"1554007\" target=\"_blank\">",
"        1554007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12781 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4885=[""].join("\n");
var outline_f4_49_4885=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220032\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220033\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049810\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445029\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049802\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220011\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219996\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049815\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220062\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049805\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049814\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220065\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220061\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049819\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049801\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049800\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300028\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222861\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220007\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220021\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049809\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049813\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049799\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049817\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049818\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049807\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049820\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12781\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12781|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/43/5814?source=related_link\">",
"      Sargramostim: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/6/25700?source=related_link\">",
"      Sargramostim: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_49_4886="Overview of carpal fractures";
var content_f4_49_4886=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of carpal fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/49/4886/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4886/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/49/4886/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4886/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/49/4886/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4886/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/49/4886/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper extremity fractures are among the most common of limb injuries; carpal fractures account for 18 percent of hand fractures and 6 percent of all fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4886/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Fractures to bones of the proximal carpal row are most frequent. Scaphoid fractures are by far the most common of the carpal fractures, and account for 10 percent of all hand fractures and 60 to 70 percent of all carpal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4886/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The incidence of fracture of the remaining bones of the carpus is small, being on the order of 0.2 to 5 percent. In general, carpal fractures occur from either direct or indirect trauma.",
"   </p>",
"   <p>",
"    Splinting is used in the initial immobilization of carpal fractures. A detailed description of the techniques for applying splints is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic provides an overview of the anatomy of the carpus, a discussion of mechanisms of injury, general principals of examination, imaging, initial care and decision making for adults with carpal fractures. More detailed discussions of fractures of each of the eight bones of the carpus are presented separately.",
"   </p>",
"   <p>",
"    Fractures through the distal radius",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ulna, although described in lay terms as \"wrist fractures\", do not involve the carpal bones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal fractures are classified primarily on the anatomic location of the fracture (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Anatomy'",
"    </a>",
"    below) and secondarily upon features including associated displacement, dislocation, and the number of fragments produced by the fracture (comminuted versus noncomminuted).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Locations of fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to fractures of the eight carpal bones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"UTD.htm?37/16/38146\">",
"     image 1",
"    </a>",
"    ) are discussed separately in the appropriate topic reviews that are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fracture of the",
"      <strong>",
"       scaphoid",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73898 \" href=\"UTD.htm?21/55/22384\">",
"       image 2",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"       \"Scaphoid fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fracture of the",
"      <strong>",
"       lunate",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52781 \" href=\"UTD.htm?24/58/25504\">",
"       image 3",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24531?source=see_link\">",
"       \"Lunate fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fracture of the",
"      <strong>",
"       triquetrum",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81364 \" href=\"UTD.htm?43/6/44142\">",
"       image 4",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36723?source=see_link\">",
"       \"Triquetral fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fracture of the",
"      <strong>",
"       pisiform",
"      </strong>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37218?source=see_link\">",
"       \"Pisiform fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fracture of the",
"      <strong>",
"       trapezium",
"      </strong>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36915?source=see_link\">",
"       \"Trapezium fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fracture of the",
"      <strong>",
"       trapezoid",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72554 \" href=\"UTD.htm?43/15/44287\">",
"       image 5",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33394?source=see_link\">",
"       \"Trapezoid fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fracture of the",
"      <strong>",
"       capitate",
"      </strong>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29251?source=see_link\">",
"       \"Capitate fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fracture of the",
"      <strong>",
"       hamate",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59836 \" href=\"UTD.htm?18/28/18894\">",
"       image 6",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9620?source=see_link\">",
"       \"Hamate fractures\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carpal bones are eight bones that comprise approximately 3 cm of the proximal hand (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"UTD.htm?37/16/38146\">",
"     image 1",
"    </a>",
"    ). These are subdivided into a proximal and distal row.",
"   </p>",
"   <p>",
"    The proximal row carpal bones (from radial to ulnar) are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Scaphoid",
"     </li>",
"     <li>",
"      Lunate",
"     </li>",
"     <li>",
"      Triquetrum (dorsal)",
"     </li>",
"     <li>",
"      Pisiform (volar)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The scaphoid actually bridges the proximal and distal row, and some authors suggest that the pisiform is more of a sesamoid (in the flexor carpi ulnaris tendon) than a true carpal bone.",
"   </p>",
"   <p>",
"    The distal row (from radial to ulnar) is comprised of the:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trapezium",
"     </li>",
"     <li>",
"      Trapezoid",
"     </li>",
"     <li>",
"      Capitate",
"     </li>",
"     <li>",
"      Hamate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hook of the hamate is on the volar aspect of the hand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Surface anatomy of the carpal bones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carpal bones can be palpated individually with a good appreciation of surface anatomy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scaphoid &mdash; The distal pole of the scaphoid can be palpated with the wrist in slight dorsiflexion by intersecting a line from the space between the index and middle finger with the distal wrist crease. It will be noted that the bone is more prominent with the wrist in radial deviation. While the scaphoid is often described as being located in the anatomical \"snuff box\" (between the extensor pollicis brevis and longus tendons just distal and slightly dorsal to the radial styloid), this is particularly true when the wrist is taken into ulnar deviation. In this position the trapezium is moved away from the radial styloid allowing the midportion of the scaphoid to be more easily palpated.",
"     </li>",
"     <li>",
"      Lunate &mdash; The lunate can be appreciated on the dorsum of the wrist just distal to the radius and in line with the middle finger. The lunate is made more prominent in this location with volar flexion of the wrist.",
"     </li>",
"     <li>",
"      Triquetrum &mdash; The triquetrum can be appreciated on the dorsum as well, and is just distal to the ulnar prominence.",
"     </li>",
"     <li>",
"      Pisiform &mdash; The pisiform is the last of the proximal row, but is palpated on the volar aspect of the hand. This very prominent rounded bone is found by intersecting a line from the 5th phalanx with the distal wrist crease. It can be noted that the pisiform is a sesamoid bone and can be moved easily if the wrist is in flexion, but becomes fixed with the wrist in extension.",
"     </li>",
"     <li>",
"      Trapezium &mdash; The trapezium is best found by palpating proximally from the thumb metacarpal. One will first note the first carpometacarpal joint and the trapezium immediately proximal.",
"     </li>",
"     <li>",
"      Trapezoid &mdash; The trapezoid is somewhat difficult to palpate but should be appreciated dorsally just proximal to the index metacarpal.",
"     </li>",
"     <li>",
"      Capitate &mdash; The capitate is a relatively long and slender bone present proximal to the middle metacarpal base. In many individuals the most proximal aspect of the middle metacarpal is \"burnished\" or more prominent.",
"     </li>",
"     <li>",
"      Hamate &mdash; The hamate can be appreciated dorsally just proximal to the base of the 5th metacarpal. The palpation can be carried around the ulnar border of the hand but becomes somewhat difficult on the volar aspect because of the muscle and tissue of the hypothenar eminence. The hook of the hamate is an important structure, as it can easily be fractured. It can be found by placing the interphalangeal (IP) joint of the thumb over the pisiform and rolling the thumb toward the space between the index and middle fingers. Deep palpation is often needed, and this pressure is often uncomfortable even in the uninjured hand.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Carpal ligaments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed discussion of the ligamentous support of the carpus is beyond the scope of this chapter. In brief, the ligaments are typically categorized as intrinsic and extrinsic. The intrinsic ligaments are the intercarpal ligaments, the extrinsic are the radio- and ulnocarpal and carpometacarpal ligaments. The volar radiocarpal ligaments of the wrist are stronger than the dorsal ligaments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Branches of the ulnar and median nerves are the main motor neural structures of the hand as they are responsible for its intrinsic muscular function. Sensation is provided by branches of the ulnar, median, and radial nerves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Median nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median nerve courses through the carpal tunnel. Trauma to the nerve at the wrist causes paresthesia or numbness of the thumb, index, middle, and a portion of the fourth (ring) digit. Related sensory loss or weakness of the adductor pollicis brevis may result from injuries to the wrist that cause fractures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Median nerve syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ulnar nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ulnar nerve also travels through a tunnel into the wrist, known as Guyon's canal, which is bordered by the pisiform and the hook of the hamate. Trauma to the nerve that accompanies a carpal fracture typically causes paresthesia or numbness in the fifth and ulnar aspect of the 4th digit and ulnar aspect of the hand. Weakness of the intrinsic muscles of the hand may occur. This anatomy necessitates evaluation of ulnar nerve function with fractures of either the hamate or pisiform. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Ulnar nerve syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Radial nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries to branches of the radial nerve at the wrist cause paresthesia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    numbness over the dorsum of the hand on the radial aspect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vessels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant vascular structures include the ulnar, radial and anterior interosseous arteries, but there are multiple anastomoses. Additionally, these vessels network into three pairs of vascular arches. The ulnar artery crosses the wrist just radial to the pisiform, and courses through Guyon's canal. The radial artery runs along the border of the anatomic snuff box. Though there is a great vascular supply to the area, the scaphoid, lunate and capitate have primarily one branch that supplies each. A branch of the radial artery gives supply to the scaphoid, but its distal to proximal course gives rise to complications with fractures of the scaphoid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history, particularly a description of the injury, is valuable in guiding imaging and examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Location of pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding description of the anatomy (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Surface anatomy of the carpal bones'",
"    </a>",
"    above) of the wrist, provides a basis for anticipating which bone is most likely to have been injured and can guide requests for imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mechanism of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient can describe the way in which the wrist was injured, the description may suggest which of the carpal bones",
"    <span class=\"nowrap\">",
"     has/have",
"    </span>",
"    been affected and affect the decision about initial imaging studies. As examples, hyperflexion and hyperextension injuries may result in avulsion fractures for the dorsal or volar aspect of the carpus, respectively, and may be best visualized by adding oblique views of the wrist to the standard AP and lateral views (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Imaging'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Axial loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axial loading of the wrist may cause fractures of the scaphoid and can result in disruption of the scapholunate ligaments resulting in scapholunate dissociation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52517 \" href=\"UTD.htm?14/30/14816\">",
"     image 7",
"    </a>",
"    ). Axial loading of the first metacarpal (thumb) is associated with vertical intraarticular fractures of the trapezium while axial loading of the index metacarpal is associated with fracture of the trapezoid with which it articulates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Wrist hyperextension",
"    </span>",
"    &nbsp;&mdash;&nbsp;An injury due to hyperextension of the wrist, as an example, due to a fall onto an outstretched hand, can force the scaphoid over the dorsum of the radius leading to fracture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73898 \" href=\"UTD.htm?21/55/22384\">",
"     image 2",
"    </a>",
"    ). The lunate and triquetrum may also be fractured due to hyperextension injuries. A linear fracture of the pisiform may occur due to a fall onto the hand but the mechanism of injury is more likely due to a blow to the bone itself rather than hyperextension of the wrist. Avulsion fracture of the pisiform, typically occurring at the distal attachment of the flexor carpi ulnaris tendon, may also result from hyperextension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Wrist hyperflexion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperflexion of the wrist may cause avulsion fractures involving the ligamentous attachments to the triquetrum",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Deviation, traction, or rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury due to forceful deviation, traction or rotation of the wrist or of the first metacarpal may cause ligamentous or capsular stresses that can result in avulsion fractures of the carpal bones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Direct blow to the palmar surface",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression of the pisiform against the triquetrum due to a direct blow (as when the hand is used as a hammer) may result in a pisiform fracture or cause chondral damage to the dorsal articular surface of the pisiform bone.",
"   </p>",
"   <p>",
"    The hook of the hamate is also vulnerable to direct pressure upon the transverse carpal ligament which can avulse the hook from the body of the hamate. A fall onto the hand, or a force transmitted by a club, racquet, or bat while playing golf or engaging in other sports may be the cause of a hamate fracture through this mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Combinations of forces",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of axial loading and hyperflexion or hyperextension, as may occur with falling onto a clenched fist, can result in capitate fractures, often with associated dislocation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard plain film radiographs include a posterior anterior (PA) and true lateral views. Other views are indicated depending upon the suspected site of fracture and these additional views are discussed in more detail in the appropriate topics. Summarized briefly the following additional plain film radiographs may be informative in certain situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oblique views of the wrist are useful to detect avulsion fractures resulting from hyperflexion, hyperextension, or injuries due to forces that cause deviation, rotation, or traction on the hand or wrist.",
"     </li>",
"     <li>",
"      A postero anterior (PA) view of the wrist with maximal ulnar deviation (scaphoid view) is useful for suspected scaphoid fractures.",
"     </li>",
"     <li>",
"      A \"carpal tunnel view\" is useful for identifying fractures of the hook of the hamate.",
"     </li>",
"     <li>",
"      A PA clenched fist view is helpful in demonstrating scapholunate instability. The space between carpal bones is usually 2 mm and a space of more than 4 mm suggests ligamentous disruption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compression fractures or minimally displaced carpal fractures may not be readily apparent on plain film radiographs of the wrist. Fractures though the waist of the scaphoid in particular may be difficult to detect and may require further investigation to thoroughly exclude a fracture.",
"   </p>",
"   <p>",
"    When there is substantial pain but plain film radiographs do not initially reveal a fracture, splinting followed by additional plain films in seven to ten days is sometimes used to detect otherwise occult fractures. Other approaches include bone scanning, magnetic resonance imaging, and ultrasonography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principals of fracture management apply to carpal fractures. The following are recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minimize further tissue injury, particularly of neural and vascular structures by immobilizing the fracture. Because substantial soft tissue swelling may occur as a result of the fracture, initial immobilization is generally achieved by applying a removable plaster or fiberglass splint. The splint can later be removed to allow reduction, fixation, and casting.",
"     </li>",
"     <li>",
"      Icing is used to minimize swelling.",
"     </li>",
"     <li>",
"      Most patients get adequate pain relief from immobilization of their wrist, ice and over-the-counter analgesics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . Opioid analgesics are occasionally needed to control pain during the first three to five days. Patients requesting opiates beyond this time should be reevaluated for irritation from a poorly fitting splint or cast, a missed secondary injury or a fracture complication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with carpal fractures awaiting urgent surgical intervention should be managed with splinting, ice and non-opioid analgesics, if possible, to avoid cognitive impairment prior to consenting to surgery.",
"   </p>",
"   <p>",
"    Further management of metacarpal fractures varies with the anatomic location of the fracture (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Locations of fractures'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional discussion of carpal fractures may be found in texts that address the issue from a orthopedic surgical standpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4886/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ], the primary care perspective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4886/abstract/2\">",
"     2",
"    </a>",
"    ], and with relation specifically to fractures in athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4886/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=see_link\">",
"       \"Patient information: Fractures (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=see_link\">",
"       \"Patient information: Common wrist injuries (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4036347\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carpal fractures are classified by anatomic location and fracture characteristics. Fractures of each carpal bone are discussed individually. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The eight carpal bones are subdivided into a proximal and distal row (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"UTD.htm?37/16/38146\">",
"       image 1",
"      </a>",
"      ). The surface anatomy of each carpal bone is described in the text. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The location of pain and mechanism provide clues to the site of injury. Particular mechanisms are associated with specific fractures, which are described in the text. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Location of pain'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard plain film radiographs include a posterior-anterior and true lateral views. Other views are indicated depending upon the suspected site of fracture. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H813357\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to acknowledge Kevin E Burroughs, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dobyns JH, Beckenbaugh RD, Bryan RS, et al. Fractures of the hand and wrist. In: Hand Surgery, 3rd, Flynn JE (Ed), Williams &amp; Wilkins, 1982.",
"    </li>",
"    <li>",
"     Eiff, MP, Hatch, RL, Calmbach, WL. Carpal fractures. In: Fracture management for primary care, 2nd ed. Chpt.5. Saunders, Philadelphia, Pa. 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4886/abstract/3\">",
"      Geissler WB. Carpal fractures in athletes. Clin Sports Med 2001; 20:167.",
"     </a>",
"    </li>",
"    <li>",
"     Seitz WH Jr, Papandrea RF. Fractures and dislocations of the wrist. In: Rockwood and Green's Fractures in Adults, 5th, Bucholz RW, Heckman JD (Eds), Lippincott, Williams, &amp; Wilkins, 2002 2002.",
"    </li>",
"    <li>",
"     Geissler W, Slade JF. Fractures of the carpal bones. In: Operative Hand Surgery, 6th, Green DP (Ed), Churchill Livingstone, 2011. p.639.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 196 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-99C72D4C66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4886=[""].join("\n");
var outline_f4_49_4886=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4036347\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Locations of fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Surface anatomy of the carpal bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Carpal ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nerves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Median nerve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ulnar nerve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Radial nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vessels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Location of pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mechanism of injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Axial loading",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Wrist hyperextension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Wrist hyperflexion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Deviation, traction, or rotation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Direct blow to the palmar surface",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Combinations of forces",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4036347\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H813357\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/196\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/196|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/16/38146\" title=\"diagnostic image 1\">",
"      Normal adult wrist AP xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/55/22384\" title=\"diagnostic image 2\">",
"      Adult scaphoid fracture xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/58/25504\" title=\"diagnostic image 3\">",
"      Lunate fracture T2 MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/6/44142\" title=\"diagnostic image 4\">",
"      Triquetral fracture oblique xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/15/44287\" title=\"diagnostic image 5\">",
"      Trapezoid edema T2 coronal MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/28/18894\" title=\"diagnostic image 6\">",
"      Hook of hamate fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/30/14816\" title=\"diagnostic image 7\">",
"      Scapholunate dissociation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29251?source=related_link\">",
"      Capitate fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9620?source=related_link\">",
"      Hamate fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24531?source=related_link\">",
"      Lunate fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=related_link\">",
"      Patient information: Common wrist injuries (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37218?source=related_link\">",
"      Pisiform fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=related_link\">",
"      Scaphoid fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36915?source=related_link\">",
"      Trapezium fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33394?source=related_link\">",
"      Trapezoid fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36723?source=related_link\">",
"      Triquetral fractures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_49_4887="Dacarbazine: Drug information";
var content_f4_49_4887=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dacarbazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/27/43444?source=see_link\">",
"    see \"Dacarbazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/45/22229?source=see_link\">",
"    see \"Dacarbazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dacarbazine for Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F156269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent (Triazene)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F156226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin's disease (combination chemotherapy):",
"     </b>",
"     I.V.: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1 and 15 every 4 weeks (ABVD regimen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Metastatic melanoma:",
"     </b>",
"     I.V.: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1-5 every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Metastatic melanoma (unlabeled dosing; in combination with cisplatin and vinblastine):",
"     </b>",
"     I.V:. 800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks (Atkins, 2008; Eton, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Soft tissue sarcoma (unlabeled use; MAID regimen):",
"     </b>",
"     I.V.: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 4 days every 3 weeks (total of 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /cycle) (Antman, 1993; Antman, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F156250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/45/22229?source=see_link\">",
"      see \"Dacarbazine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin's disease (combination chemotherapy):",
"     </b>",
"     I.V.: 375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1 and 15 every 4 weeks (ABVD regimen; Hutchinson, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F156227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F156228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling does not contain dosage adjustment guidelines. The following guidelines have been used by some clinicians (Kintzel, 1995):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 80% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Administer 70% of dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F156229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling does not contain adjustment guidelines. May cause hepatotoxicity; monitor closely for signs of toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F156205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse over 30-60 minutes; rapid infusion may cause severe venous irritation. May also be administered as a continuous infusion (unlabeled administration rate) depending on the protocol.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Extravasation management:",
"     </b>",
"     Local pain, burning sensation, and irritation at the injection site may be relieved by local application of hot packs. If extravasation occurs, apply cold packs. Protect exposed tissue from light following extravasation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F156275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, sterile water for injection;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, aztreonam, doxorubicin liposomal, etoposide phosphate, filgrastim, fludarabine, granisetron, melphalan, ondansetron, paclitaxel, palonosetron, sargramostim, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, cefepime, piperacillin/tazobactam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F156203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of malignant melanoma, Hodgkin's disease",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9294234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of soft-tissue sarcomas, islet cell tumors, pheochromocytoma, medullary carcinoma of the thyroid",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F156278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dacarbazine may be confused with procarbazine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F156267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea and vomiting (&gt;90%), anorexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Myelosuppression (onset: 5-7 days; nadir: 7-10 days; recovery: 21-28 days), leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain on infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infrequent, postmarketing, and/or case reports: Anaphylactic reactions, anemia, diarrhea, eosinophilia, erythema, facial flushing, facial paresthesia, flu-like syndrome (fever, myalgia, malaise), hepatic necrosis, hepatic vein occlusion, liver enzymes increased (transient), paresthesia, photosensitivity, rash, renal functions test abnormalities, taste alteration, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F156208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dacarbazine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F156191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: May occur following dacarbazine administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Bone marrow suppression is a common toxicity;",
"     </b>",
"     leukopenia and thrombocytopenia may be severe; may result in treatment delays or discontinuation; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinogenic/teratogenic:",
"     <b>",
"      [U.S. Boxed Warning]: May be carcinogenic and/or teratogenic.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: May result in tissue damage and severe pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects:",
"     <b>",
"      [U.S. Boxed Warning]: Hepatotoxicity with hepatocellular necrosis and hepatic vein thrombosis has been reported (rare),",
"     </b>",
"     usually with combination chemotherapy, but may occur with dacarbazine alone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; half-life is increased, monitor for toxicity and consider dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; half-life is increased, monitor for toxicity and consider dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"     Carefully evaluate the potential benefits of therapy against the risk for toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F156264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2E1 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Inhibitors (Moderate): May decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Inhibitors (Strong): May decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May decrease the serum concentration of Dacarbazine. Sorafenib may also increase the concentration of dacarbazine's active metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F156219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5571043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: This agent is carcinogenic and/or teratogenic when used in animals;",
"     </b>",
"     adverse effects have been observed in animal studies. There are no adequate and well-controlled trials in pregnant women; use in pregnancy only if the potential benefit outweighs the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F156238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10191927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Dacarbazine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $11.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (1): $12.71",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F156200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, liver function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F156210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ai Li Da (CL);",
"     </li>",
"     <li>",
"      D.T.I.C. (DE);",
"     </li>",
"     <li>",
"      D.T.I.C.-Dome (AT, SE, ZA);",
"     </li>",
"     <li>",
"      Dabaz (IN, PE);",
"     </li>",
"     <li>",
"      DAC (SG);",
"     </li>",
"     <li>",
"      Dacarb (BR);",
"     </li>",
"     <li>",
"      Dacarbazin (BG, CZ, HN, HU);",
"     </li>",
"     <li>",
"      Dacarbazina (ES);",
"     </li>",
"     <li>",
"      Dacarbazine (NZ);",
"     </li>",
"     <li>",
"      Dacarbazine DBL (MY);",
"     </li>",
"     <li>",
"      Dacarbazine Dome (DK);",
"     </li>",
"     <li>",
"      Dacarbazine For Injection (AU);",
"     </li>",
"     <li>",
"      Dacatic (FI);",
"     </li>",
"     <li>",
"      Dacin (CH);",
"     </li>",
"     <li>",
"      Deticene (AR, CN, CZ, EG, FR, GR, HN, HR, IL, IT, NL, PL, PT, RU, TR, UY);",
"     </li>",
"     <li>",
"      Deticine (HU);",
"     </li>",
"     <li>",
"      Detilem (MX);",
"     </li>",
"     <li>",
"      Detimedac (DE);",
"     </li>",
"     <li>",
"      DTI (HK, KP);",
"     </li>",
"     <li>",
"      DTIC (AT, ZA);",
"     </li>",
"     <li>",
"      DTIC-Dome (BE, GB, KP);",
"     </li>",
"     <li>",
"      Duticin (PH, PK);",
"     </li>",
"     <li>",
"      Oncocarbil (AR, PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F156190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alkylating agent which is converted to the active alkylating metabolite MTIC [(methyl-triazene-1-yl)-imidazole-4-carboxamide] via the cytochrome P450 system. The cytotoxic effects of MTIC are manifested through alkylation (methylation) of DNA at the O",
"     <sup>",
"      6",
"     </sup>",
"     , N",
"     <sup>",
"      7",
"     </sup>",
"     guanine positions which lead to DNA double strand breaks and apoptosis. Non-cell cycle specific.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F156207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.6 L/kg, exceeding total body water; suggesting binding to some tissue (probably liver)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to the active metabolite MTIC [(methyl-triazene-1-yl)-imidazole-4-carboxamide]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: Initial: 20-40 minutes, Terminal: 5 hours; Patients with renal and hepatic dysfunction: Initial: 55 minutes, Terminal: 7.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~40% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antman K, Crowley J, Balcerzak SP, et al, &ldquo;An Intergroup Phase III Randomized Study of Doxorubicin and Dacarbazine With or Without Ifosfamide and Mesna in Advanced Soft Tissue and Bone Sarcomas,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(7):1276-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/8315425/pubmed\" id=\"8315425\" target=\"_blank\">",
"        8315425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman K, Crowley J, Balcerzak SP, et al, &ldquo;A Southwest Oncology Group and Cancer and Leukemia Group B phase II Study of Doxorubicin, Dacarbazine, Ifosfamide, and Mesna in Adults With Advanced Osteosarcoma, Ewing's Sarcoma, and Rhabdomyosarcoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1998, 82(7):1288-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/9529020/pubmed\" id=\"9529020\" target=\"_blank\">",
"        9529020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Atkins MB, Hsu J, Lee S, et al, &ldquo;Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(35):5748-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/19001327/pubmed\" id=\"19001327\" target=\"_blank\">",
"        19001327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonfante V, Santoro A, Viviani S, et al, &ldquo;ABVD in the Treatment of Hodgkin's Disease,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1992, 19(2 Suppl 5):38-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/1384143/pubmed\" id=\"1384143\" target=\"_blank\">",
"        1384143",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buesa JM and Urrechaga E, &ldquo;Clinical Pharmacokinetics of High-Dose DTIC,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1991, 28(6):475-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/1934251/pubmed\" id=\"1934251\" target=\"_blank\">",
"        1934251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engert A, Franklin J, Eich HT, et al,  &ldquo;Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(23):3495-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/17606976/pubmed\" id=\"17606976\" target=\"_blank\">",
"        17606976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eton O, Legha SS, Bedikian AY, et al, &ldquo;Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(8):2045-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/11956264/pubmed\" id=\"11956264\" target=\"_blank\">",
"        11956264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutchinson RJ, Fryer CJ, Davis PC, et al, &ldquo;MOPP or Radiation in Addition to ABVD in the Treatment of Pathologically Staged Advanced Hodgkin's Disease in Children: Results of the Children's Cancer Group Phase III Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(3):897-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/9508171/pubmed\" id=\"9508171\" target=\"_blank\">",
"        9508171",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, \"Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,\"",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marchesi F, Turriziani M, Tortorelli G, et al, &ldquo;Triazene Compounds: Mechanism of Action and Related DNA Repair Systems,&rdquo;",
"      <i>",
"       Pharmacol Res",
"      </i>",
"      , 2007, 56(4):275-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/17897837/pubmed\" id=\"17897837\" target=\"_blank\">",
"        17897837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meyer RM, Gospodarowicz MK, Connors JM, et al, &ldquo;Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(21):4634-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/15837968/pubmed\" id=\"15837968\" target=\"_blank\">",
"        15837968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Middleton MR, Grob JJ, Aaronson N, et al, &ldquo;Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(1):158-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/10623706/pubmed\" id=\"10623706\" target=\"_blank\">",
"        10623706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Hodgkin Disease/Lymphoma,&rdquo; Version 1.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/hodgkins.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Melanoma,&rdquo; Version 2.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN) &ldquo;Practice Guidelines in Oncology&trade;: Neuroendocrine Tumors,&rdquo; Version 2.2009. Available at file://www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Soft Tissue Sarcoma,&rdquo; Version 3.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Thyroid Carcinoma,&rdquo; Version 1.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nocera M, Baudin E, Pellegriti G, et al, &ldquo;Treatment of Advanced Medullary Thyroid Cancer With an Alternating Combination of Doxorubicin-Streptozocin and 5 FU-Dacarbazine, Groupe d'Etude des Tumeurs &agrave; Calcitonine (GETC),&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2000, 83(6):715-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/10952773/pubmed\" id=\"10952773\" target=\"_blank\">",
"        10952773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramanathan RK, Cnaan A, Hahn RG, et al, &ldquo;Phase II Trial of Dacarbazine (DTIC) in Advanced Pancreatic Islet Cell Carcinoma, Study of the Eastern Cooperative Oncology Group-E6282,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2001, 12(8):1139-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/11583197/pubmed\" id=\"11583197\" target=\"_blank\">",
"        11583197",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rusthoven JJ, Quirt IC, Iscoe NA, et al, &ldquo;Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Response Rates of Carmustine, Dacarbazine, and Cisplatin With and Without Tamoxifen in Patients With Metastatic Melanoma. National Cancer Institute of Canada Clinical Trials Group&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(7):2083-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/8683240/pubmed\" id=\"8683240\" target=\"_blank\">",
"        8683240",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Straus DJ, Portlock CS, Qin J, et al, &ldquo;Results of a Prospective Randomized Clinical Trial of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Followed by Radiation Therapy (RT) Versus ABVD Alone for Stages I, II, and IIIA Nonbulky Hodgkin Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 104(12):3483-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/49/4887/abstract-text/15315964/pubmed\" id=\"15315964\" target=\"_blank\">",
"        15315964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9316 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4887=[""].join("\n");
var outline_f4_49_4887=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708693\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156223\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156269\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156226\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156250\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156227\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156228\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156229\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156202\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156187\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156205\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156275\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156203\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9294234\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156278\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156267\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156208\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156191\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156264\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156196\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156219\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156198\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5571043\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156238\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10191927\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323091\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156200\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156210\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156190\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156207\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9316\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9316|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/27/43444?source=related_link\">",
"      Dacarbazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/45/22229?source=related_link\">",
"      Dacarbazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_49_4888="Muscle biopsy dermatomyositis";
var content_f4_49_4888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Perivascular inflammation in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin and eosin stain (20x) of a muscle biopsy from a patient with dermatomyositis showing perivascular and perimysial inflammation, as well as perifascicular necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William W Pendlebury, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4888=[""].join("\n");
var outline_f4_49_4888=null;
var title_f4_49_4889="Treatment of precocious puberty";
var content_f4_49_4889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of precocious puberty",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/49/4889/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4889/contributors\">",
"     Paul Saenger, MD, MACE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/49/4889/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4889/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4889/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4889/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/49/4889/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4889/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4889/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/49/4889/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H23810861\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precocious puberty had been defined as the onset of secondary sexual development before the age of eight years in girls and nine years in boys. Because of trends towards earlier pubertal development, a substantial portion of healthy girls will have breast or pubic hair development before this age, and extensive evaluation and treatment usually are not required.",
"   </p>",
"   <p>",
"    If the evaluation leads to a diagnosis of precocious puberty, treatment may be considered. The treatment options depend upon the cause of the precocious puberty, as discussed below. The definition, etiology, and evaluation of precocious puberty are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23808232\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precocious puberty can be classified based upon the underlying pathologic process. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Gonadotropin-dependent precocious puberty",
"      </strong>",
"      &mdash; Gonadotropin-dependent precocious puberty (GDPP, also known as central precocious puberty or true precocious puberty) is caused by early maturation of the hypothalamic-pituitary-gonadal axis. GDPP is characterized by sequential maturation of breasts and pubic hair in girls, and by testicular enlargement and pubic hair development in boys. In these patients, the sexual characteristics are appropriate for the child's gender (isosexual). GDPP is idiopathic in more than 80 percent of cases, and almost all idiopathic cases occur in girls. In a small number of girls and boys, GDPP is caused by a central nervous system lesion (",
"      <a class=\"graphic graphic_table graphicRef52565 \" href=\"UTD.htm?41/47/42747\">",
"       table 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H8#H8\">",
"       \"Definition, etiology, and evaluation of precocious puberty\", section on 'Causes of gonadotropin dependent precocious puberty (GDPP)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Gonadotropin-independent precocious puberty",
"      </strong>",
"      &mdash; Gonadotropin-independent precocious puberty (GIPP, also known as peripheral precocious puberty or pseudoprecocious puberty) is caused by excess secretion of sex hormones (estrogens or androgens) derived either from the gonads or adrenal glands (",
"      <a class=\"graphic graphic_table graphicRef59268 \" href=\"UTD.htm?38/57/39837\">",
"       table 1B",
"      </a>",
"      ). Puberty may be appropriate for the child&rsquo;s gender (isosexual) or inappropriate, with virilization of girls and feminization of boys (contrasexual). Similar findings can be induced by inadvertent exposure to exogenous sources of sex steroids or, in boys, by ectopic tumoral production of gonadotropin (ie, human chorionic gonadotropin, hCG). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H9#H9\">",
"       \"Definition, etiology, and evaluation of precocious puberty\", section on 'Causes of gonadotropin independent precocious puberty (GIPP)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Incomplete precocious puberty",
"      </strong>",
"      &mdash; Incomplete precocious puberty is defined as isolated breast development in girls (premature thelarche) or isolated male hormone-mediated sexual characteristics, such as pubic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      axillary hair, acne, and apocrine odor in boys or girls that results from increased adrenal androgen production (premature adrenarche) (",
"      <a class=\"graphic graphic_table graphicRef72054 \" href=\"UTD.htm?41/53/42843\">",
"       table 1C",
"      </a>",
"      ). Both of these disorders can be a variant of normal puberty. However, these children should be monitored because some progress to precocious puberty. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H13#H13\">",
"       \"Definition, etiology, and evaluation of precocious puberty\", section on 'Types of incomplete precocious puberty'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23808992\">",
"    <span class=\"h1\">",
"     TREATMENT FOR GDPP",
"    </span>",
"    &nbsp;&mdash;&nbsp;When gonadotropin-dependent precocious puberty (GDPP) is caused by an identifiable central nervous system (CNS) lesion, therapy is directed toward the underlying pathology when possible. An important exception is a benign hypothalamic hamartoma, which is almost always left in situ and monitored neuroradiologically over time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most patients with GDPP, the primary treatment option is a gonadotropin-releasing hormone (GnRH) agonist. This treatment is often appropriate for patients with idiopathic GDPP, for GDPP caused by a benign hamartoma, or for secondary activation of GDPP, which may occur in patients who initially present with gonadotropin-independent precocious puberty (GIPP) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/2\">",
"     2",
"    </a>",
"    ]. For such patients, treatment with GnRH agonists is generally safe and effective. However, not all patients require treatment, as outlined in the following section. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809000\">",
"    <span class=\"h2\">",
"     Decision to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of treatment for GDPP is to allow a child to grow to a normal adult height. Therefore, the decision to treat should include analysis of the predicted height benefit from treatment, as discussed in this section. Parents are often concerned about the prospect of early menses, which might be distressing in a very young girl. However, treatment primarily to address perceived psychosocial consequences of precocious puberty should be approached with caution because of scant data in this area [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision of whether to treat GDPP with a GnRH agonist depends upon the child&rsquo;s age, the rate of pubertal progression (sexual maturation), height velocity, and the estimated adult height as determined from the rate of bone age advancement. In the following discussion, pubertal progression would be considered slow if there is no change in stage of breast, pubic hair, or genital development during six or more months of observation (",
"    <a class=\"graphic graphic_table graphicRef72017 \" href=\"UTD.htm?40/24/41356\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/4\">",
"     4",
"    </a>",
"    ]. Height velocity is considered accelerated if it is more than 6 cm per year. The relationship between pubertal stages and height velocity in normally developing children is outlined in the figure (",
"    <a class=\"graphic graphic_figure graphicRef52047 graphicRef72046 \" href=\"UTD.htm?26/57/27543\">",
"     figure 1A-B",
"    </a>",
"    ) and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link&amp;anchor=H3#H3\">",
"     \"Normal puberty\", section on 'Pubertal changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical decision-making is guided by the following considerations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Age",
"      </strong>",
"      &mdash; Children with GDPP who present at a younger age and have a rapid progression of maturation will have early epiphyseal fusion and reduced adult height if they are not treated. These children will benefit the most from therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3\">",
"       3",
"      </a>",
"      ]. In contrast, children who present close to the age of normal puberty or who have a very slowly progressive variant of precocious puberty may not require any therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/5-8\">",
"       5-8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For girls, GnRH agonist treatment results in an average gain in adult height of 9 to 10 cm if therapy is begun before the age of six, and 4 to 7 cm if begun between six and eight years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3\">",
"       3",
"      </a>",
"      ]. However, the height gain from GnRH therapy would be on the lower end of this range if the child&rsquo;s bone age is advanced.",
"     </li>",
"     <li>",
"      For boys, fewer data are available. One study estimated that GnRH treatment beginning at an average of 7.6 years resulted in a mean height gain of 6.2 &plusmn; 8.7 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/9\">",
"       9",
"      </a>",
"      ]. An expert panel concluded that it is reasonable to consider GnRH agonist treatment for boys with progressive GDPP if they present before nine years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3\">",
"       3",
"      </a>",
"      ]. As in girls, the height gain is likely to be attenuated if the child has advanced bone age at the initiation of GnRH agonist therapy.",
"     </li>",
"     <li>",
"      Children who present later and have passed their peak height velocity may present with slow height velocity for their chronologic age. Although GnRH agonist therapy would be expected to further reduce the height velocity, it will also delay epiphyseal fusion. The net result is usually slow but progressively increases in predicted height, which may not be of sufficient clinical value to justify treatment in an individual patient [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3,4,10\">",
"       3,4,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rate of maturation",
"      </strong>",
"      &mdash; If precocious puberty is slowly progressive, it is unlikely to compromise adult height potential. In a study of 16 such girls who were followed for 12 years without treatment, all reached normal adult height [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/6\">",
"       6",
"      </a>",
"      ]. Despite the early onset of breast development in this group, menarche occurred at a normal age (average age 11 years). Similarly, in a group of 35 boys with slowly progressive puberty (defined as progression from Tanner stage 2 to 3 over more than 18 months) who were not treated, adult height was within the range of their target height (",
"      <a class=\"graphic graphic_table graphicRef55329 \" href=\"UTD.htm?8/1/8220\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/8\">",
"       8",
"      </a>",
"      ]. Clinical experience has shown that many cases of precocious puberty, particularly in girls with onset after six years of age, will be slowly progressive.",
"     </li>",
"     <li>",
"      <strong>",
"       Height prediction",
"      </strong>",
"      &mdash; If the height prediction (based upon the height and height velocity, combined with bone age) is above 150 cm in girls and above 160 cm in boys, therapy is probably not needed to achieve normal adult height, and a conservative approach is warranted [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link&amp;anchor=H4#H4\">",
"       \"Diagnostic approach to short stature\", section on 'Prediction of height potential'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, a child presenting with GDPP before the age of six with breast and pubic hair development, advanced bone age, and accelerated height velocity is likely to benefit from GnRH agonist therapy. Conversely, in a child with early onset of puberty and historically slow progression of pubertal development and height velocity, it is appropriate to monitor without treatment for three to six months to establish the pace of the pubertal progression (",
"    <a class=\"graphic graphic_table graphicRef72017 \" href=\"UTD.htm?40/24/41356\">",
"     table 2",
"    </a>",
"    ) before making treatment decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809007\">",
"    <span class=\"h2\">",
"     GnRH agonist treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For GDPP, GnRH agonist therapy is a safe and effective treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/8,10-17\">",
"     8,10-17",
"    </a>",
"    ]. GnRH agonist administration results in an initial stimulation of pituitary gonadotropin secretion, followed by a complete but reversible suppression of the pituitary-gonadal axis, making this an ideal option for treatment of precocious puberty and other diseases mediated by gonadal steroids. GnRH agonist administration slows accelerated puberty and improves final height compared with pretreatment predicted height. Treatment should be given until it appears that it is safe and appropriate for puberty to proceed. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809014\">",
"    <span class=\"h3\">",
"     Effects on height",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of long-term treatment with a GnRH agonist was illustrated in a report of 98 children with GDPP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/10\">",
"     10",
"    </a>",
"    ]. Treatment with deslorelin or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/57/917?source=see_link\">",
"     histrelin",
"    </a>",
"    was begun at an average age of 5.3 years and continued for an average of 6.1 years. The final height in the 80 girls was 159 &plusmn; 7.6 cm, which was greater than the pretreatment predicted height of 149.3 &plusmn; 9.6 cm but less than the midparental height of 163.7 &plusmn; 5.6 cm. Final height in the 18 boys was 171.1 &plusmn; 8.7 cm, greater than the pretreatment predicted height of 156.1 &plusmn; 14.2 cm but less than midparental height of 178.3 &plusmn; 5.2 cm. As expected, earlier initiation of treatment led to the best outcomes: in 54 patients who had less than a two-year delay between the onset of puberty and initiation of treatment, adult heights were similar to the midparental height, suggesting that treatment was effective in preserving growth potential; 21 children exceeded the midparental height.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809021\">",
"    <span class=\"h3\">",
"     Formulations and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained-release formulations of several GnRH agonists have been developed for monthly or three-monthly dosing; the three-monthly dosing preparations are not available in the United States (",
"    <a class=\"graphic graphic_table graphicRef72979 \" href=\"UTD.htm?41/16/42252\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/4\">",
"     4",
"    </a>",
"    ]. The choice of GnRH agonist formulation depends on patient and clinician preference and local regulatory approvals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3\">",
"     3",
"    </a>",
"    ]. These preparations have not been directly compared in randomized trials but appear to be comparably effective in suppressing the gonadotropic axis, as illustrated by the following examples: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An open-label trial compared dosing schedules of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/61/25558?source=see_link\">",
"       leuprolide",
"      </a>",
"      acetate 7.5 mg monthly, 3.5 mg monthly, or 11.25 mg every three months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/18\">",
"       18",
"      </a>",
"      ]. These schedules reduced LH by 1.3, 1.73, and 2.13",
"      <span class=\"nowrap\">",
"       mIU/mL,",
"      </span>",
"      respectively, and FSH concentrations by 2.86, 3.91, and 3.96",
"      <span class=\"nowrap\">",
"       mIU/mL,",
"      </span>",
"      respectively. Sex steroid concentrations were also inhibited. Because of the short duration of this study, the important clinical outcomes of growth and slowing accelerated puberty could not be evaluated. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      A randomized trial compared dosing schedules of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/61/25558?source=see_link\">",
"       leuprolide",
"      </a>",
"      acetate 7.5 mg monthly, 11.25 mg every three months, and 22.5 mg every three months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/19\">",
"       19",
"      </a>",
"      ]. The incidence of subjects with inadequate pubertal suppression (stimulated LH levels &gt;4",
"      <span class=\"nowrap\">",
"       IU/L)",
"      </span>",
"      during the first year of therapy was higher in the group treated with 11.25 mg every three months",
"      <span class=\"nowrap\">",
"       (7/21",
"      </span>",
"      subjects, 30 percent), as compared to the 7.5 mg monthly group",
"      <span class=\"nowrap\">",
"       (1/18",
"      </span>",
"      subjects) and 22.5 mg every three month group",
"      <span class=\"nowrap\">",
"       (1/13",
"      </span>",
"      subjects). However, most of these cases resolved on a subsequent visit, and inadequate suppression was rare during the second year of therapy. Thus, the 11.25 mg three month preparation appears to be efficacious for most patients, and the 22.5 mg dosage is slightly more effective during the first year of therapy. &nbsp; &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      In an open-label trial, a depot preparation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/11/9398?source=see_link\">",
"       triptorelin",
"      </a>",
"      was administered at a dose of 11.25 mg every three months for 12 months. This treatment inhibited the gonadotropic axis, as demonstrated by peak LH values after GnRH stimulation of less than 3",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      in over 95 percent of children after 6 and 12 months of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/20\">",
"       20",
"      </a>",
"      ]. However, the effects on estradiol and testosterone suppression were not as consistent as those achieved with monthly administration. &nbsp;",
"     </li>",
"     <li>",
"      A formulation of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/57/917?source=see_link\">",
"       histrelin",
"      </a>",
"      provides long-term gonadotropin suppression in children with GDPP for up to one year with a single implantation. In a multicenter trial of this formulation in boys and girls with GDPP, peak LH and estradiol or testosterone were effectively suppressed, and no significant adverse effects were noted [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/21\">",
"       21",
"      </a>",
"      ]. Positive two-year safety and efficacy data have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/22\">",
"       22",
"      </a>",
"      ]. This formulation may provide treatment for GDPP without the pain and inconvenience of monthly injections but does require a minor surgical procedure to insert the implant and to remove it. Preliminary data suggest that the suppressive action of the implant may last well beyond 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A typical approach to GnRH agonist dosing using formulations available in the United States is described below. (See",
"    <a class=\"local\" href=\"#H23809042\">",
"     'Our approach'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809028\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be evaluated every three to six months for pubertal development and growth, and bone age should also be measured radiographically every 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]. If treatment is effective, further breast and testicular development should cease, and height velocity and rate of bone age advancement should decline. Pubic hair stage may advance due to adrenarche despite effective treatment with GnRH agonists because these have no effect on adrenal androgen production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/25\">",
"     25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    One method of monitoring these patients is to perform serial measurements of LH and sex steroid levels (estradiol in girls and testosterone in boys). In our practice, we monitor LH and sex steroid concentrations one to two months after initiating therapy or changing a dose. These are measured just prior to administering a dose of GnRH agonist. In general, suppression of LH and sex steroids to prepubertal levels suggests adequate dosing of the GnRH agonist. However, the results should be interpreted with caution because they are not well correlated with clinical response to the GnRH agonist treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there is clinical evidence of pubertal progression, one of the following methods should be used to determine whether the dose of GnRH agonist is sufficient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GnRH (or GnRH agonist) stimulation test &mdash; The peptide GnRH is available in many countries but not the United States. Therefore, a GnRH agonist is used for stimulation testing.&nbsp;The goal of stimulation testing when performed during GnRH agonist therapy is to assess the degree of suppression of the pituitary-gonadal axis. When there is complete suppression, there is no significant LH response to either GnRH or GnRHa stimulation. On the other hand, if the axis is",
"      <strong>",
"       not",
"      </strong>",
"      completely suppressed (due to inadequate GnRHa dose or noncompliance), the serum LH concentration will rise briefly within two hours in response to the stimulation dose of GnRH or GnRHa, because the pituitary gonadotrophs are not completely desensitized. By contrast, the goal of the pretreatment diagnostic GnRH agonist stimulation test is to determine if there has been maturation of the hypothalamic-pituitary-gonadal axis; if so, the LH concentration will rise in response to GnRH or GnRH agonist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H18#H18\">",
"       \"Definition, etiology, and evaluation of precocious puberty\", section on 'Serum LH concentrations after GnRH agonist stimulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measurement of serum LH concentrations after a therapeutic dose of GnRHa &mdash; Alternatively, some providers assess for adequate dosing of GnRH agonist therapy by measuring serum LH 30 to 90 minutes after the injection of a therapeutic GnRH dose [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3,27\">",
"       3,27",
"      </a>",
"      ]. In one study, a LH value of &lt;2.5",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      measured 90 minutes after administration of GnRHa confirmed adequate pubertal suppression with sensitivity and specificity of 100 and 88 percent, respectively (as compared with the gold standard of intravenous GnRH stimulation test) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/28\">",
"       28",
"      </a>",
"      ]. Therefore, patients with LH concentrations greater than this cutoff should be further evaluated with a GnRH stimulation test to determine whether the pituitary is adequately suppressed. Note that during the first few months after initiating GnRHa treatment LH values are not expected to be suppressed, and they tend to rise after each dose of GnRHa. &nbsp;",
"     </li>",
"     <li>",
"      Random LH levels of less than 0.1",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      prior to the next GnRHa dose are also accepted by many clinicians as a sign of good suppression. However, LH levels above this threshold are not necessarily a sign of inadequate pubertal suppression, particularly in the first year of therapy, when basal LH levels are often elevated above prepubertal norms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/29\">",
"       29",
"      </a>",
"      ]. In a group of patients treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/57/917?source=see_link\">",
"       histrelin",
"      </a>",
"      implants, more than half had random LH levels in the pubertal range after six months of therapy, although there was no evidence of clinical progression of puberty and GnRHa stimulation testing confirmed pubertal suppression [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/30\">",
"       30",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone density may decrease during prolonged therapy, but bone mass is regained after treatment, and peak bone mass is normal, so monitoring of bone density is not required [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3,31\">",
"     3,31",
"    </a>",
"    ]. We suggest ensuring adequate intake of calcium and vitamin D during and after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809035\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with GnRH agonists appears to have no significant long-term effects on the pituitary-gonadal axis, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal puberty (including menstruation in girls) returns on average 16 months after termination of GnRH agonist therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment with GnRH agonists does not affect gonadal function during adulthood. This was shown in a randomized trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/11/9398?source=see_link\">",
"       triptorelin",
"      </a>",
"      treatment in girls with slowly progressive GDPP with long-term follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/32\">",
"       32",
"      </a>",
"      ]. Girls were treated with triptorelin for an average of 25 months, or observation alone. At follow-up in early adulthood (mean of 33 months after cessation of treatment), there were no significant differences between the groups in serum hormone levels or ovarian or uterine volume, and these measures were also similar to normal controls.",
"     </li>",
"     <li>",
"      Small studies in boys also show normal gonadal function after treatment with GnRH agonists [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although obesity is associated with earlier pubertal development, long-term treatment with GnRH agonists does not appear to cause or exacerbate obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/3,33\">",
"     3,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809042\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of GnRH agonist formulation depends on patient and clinician preference and local regulatory approvals. A variety of dosing schemes appear to be effective, and starting doses used in Europe tend to be somewhat lower than those in the United States (",
"    <a class=\"graphic graphic_table graphicRef72979 \" href=\"UTD.htm?41/16/42252\">",
"     table 4",
"    </a>",
"    ). The dose chosen for an individual patient should be adjusted based on the clinical response. Families should be counseled that some vaginal bleeding may occur after the initiation of GnRH agonist therapy, due to withdrawal of progesterone. &nbsp;",
"   </p>",
"   <p>",
"    In our practice, we generally use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/61/25558?source=see_link\">",
"     leuprolide",
"    </a>",
"    depot (Lupron Depot PED&reg; [one month]) given intramuscularly (IM) once monthly, with a starting dose of either 7.5 mg, 11.25 mg, or 15 mg, depending on the child's weight (approximately 0.3",
"    <span class=\"nowrap\">",
"     mg/kg/dose).",
"    </span>",
"    Younger children (girls &lt;8 years and boys &lt;9 years) may require higher per-kg doses of GnRH agonist than older children.",
"   </p>",
"   <p>",
"    Alternatively, we offer a three month preparation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/61/25558?source=see_link\">",
"     leuprolide",
"    </a>",
"    depot (Lupron Depot PED&reg; [three month]) to families who desire the less frequent administration, although administration of this dosing form is supported by somewhat less clinical evidence (see",
"    <a class=\"local\" href=\"#H23809021\">",
"     'Formulations and dosing'",
"    </a>",
"    above). In most patients we start with the lower dose (11.25 mg) and titrate upwards if puberty is not adequately suppressed. However, for males",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    children with hypothalamic hamartomas (groups in which control of puberty is more difficult), we generally select the 30 mg dose for three month administration. The side effect profile of these three monthly preparations appears to be independent of the dose. &nbsp;",
"   </p>",
"   <p>",
"    We monitor the response to the GnRH agonist by assessing pubertal development and growth every three months, and adjust the dose of GnRH agonist upward if pubertal progression is not suppressed. We also measure LH or sex steroid levels, or perform a GnRH stimulation test, one to two months after initiation of therapy or change in dose, as described above. (See",
"    <a class=\"local\" href=\"#H23809028\">",
"     'Monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We generally continue treatment until about age 11 in girls, and age 12 in boys. The decision of when to discontinue GnRH agonist therapy is individualized; contributing factors include the age of the child, bone age and height age, predicted height, and social desire to join their peers in puberty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809049\">",
"    <span class=\"h1\">",
"     TREATMENT FOR GIPP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotropin-independent precocious puberty (GIPP, also referred to as peripheral precocious puberty) is caused by excess secretion of sex hormones (estrogens or androgens) derived from the gonads, adrenal glands, or exogenous sources (",
"    <a class=\"graphic graphic_table graphicRef59268 \" href=\"UTD.htm?38/57/39837\">",
"     table 1B",
"    </a>",
"    ). The causes and evaluation of GIPP are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H9#H9\">",
"     \"Definition, etiology, and evaluation of precocious puberty\", section on 'Causes of gonadotropin independent precocious puberty (GIPP)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7811799\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"   </p>",
"   <p>",
"    GIPP does not respond to GnRH agonist therapy. Instead, treatment is directed at the underlying pathology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with tumors of the testis, adrenal gland, and ovary are treated by surgery. Those with hCG-secreting tumors may require some combination of surgery, radiation therapy, and chemotherapy depending upon the site and histologic type.",
"     </li>",
"     <li>",
"      A large functioning follicular cyst of the ovary is the most common cause of GIPP in girls. Cysts develop and regress spontaneously, so conservative management without surgery is generally appropriate [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/34\">",
"       34",
"      </a>",
"      ]. Patients should be followed to document regression of the cyst. &nbsp;",
"     </li>",
"     <li>",
"      Children whose sexual precocity is caused by exposure to exogenous sex steroids must have that exposure identified and removed; after removal of the exposure, the pubertal changes are likely to regress.",
"     </li>",
"     <li>",
"      Children with identifiable defects in adrenal steroidogenesis, such as classic congenital adrenal hyperplasia, should be treated with glucocorticoid therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"       \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    McCune-Albright syndrome and familial male-limited precocious puberty require a different approach because they are caused by mutations resulting in overstimulation of the tissues that produce sex steroids. To preserve fertility, children with these disorders should be treated with drugs that inhibit gonadal steroidogenesis or gonadal steroid action, rather than surgery, as discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809056\">",
"    <span class=\"h2\">",
"     McCune-Albright syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;McCune-Albright Syndrome (MAS) is a rare disorder defined as the triad of peripheral precocious puberty, caf&eacute;-au-lait skin pigmentation, and fibrous dysplasia of bone. The clinical presentation and diagnosis of MAS is discussed separately. Affected girls tend to overproduce estrogens, whereas affected boys overproduce androgens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H3989453#H3989453\">",
"     \"Definition, etiology, and evaluation of precocious puberty\", section on 'McCune-Albright syndrome'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In girls with MAS, testolactone has been used to inhibit aromatization of androgen to estrogen (",
"    <a class=\"graphic graphic_figure graphicRef62460 \" href=\"UTD.htm?40/33/41502\">",
"     figure 2",
"    </a>",
"    ); this treatment has been at least partially successful in decreasing the recurrence of ovarian cysts and thereby slowing pubertal progression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/35\">",
"     35",
"    </a>",
"    ]. However, a follow-up report suggested that there was a distinct loss in efficacy over time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/36\">",
"     36",
"    </a>",
"    ]. Treatment with the later-generation aromatase inhibitors fadrozole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    also appears to be largely ineffective for long-term treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/37-40\">",
"     37-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other approaches for girls with MAS seek to block the effects of estrogens on end-organs. Treatment with the antiestrogen",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/6/43111?source=see_link\">",
"     tamoxifen",
"    </a>",
"    has been effective in reducing vaginal bleeding, but long-term studies of outcomes such as skeletal growth are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few patients with MAS will develop a component of GDPP. This is probably caused by prolonged exposure to elevated levels of sex steroids and is most often found in patients with advanced bone age. Such patients may respond to adjuvant treatment with a GnRH agonist, as do other children with GDPP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23809007\">",
"     'GnRH agonist treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Very rarely, boys can be affected by MAS, in which case they tend to overproduce testosterone. A few reports describe successful treatment of these boys with an antiandrogen, in combination with an aromatase inhibitor, similar to the regimen used for familial male-limited precocious puberty described below (see",
"    <a class=\"local\" href=\"#H23809063\">",
"     'Familial male-limited precocious puberty'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/2\">",
"     2",
"    </a>",
"    ]. However, due to the rarity of this disorder in boys, information about treatment outcomes is very limited. The pathogenesis and presentation of MAS are outlined in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H3989453#H3989453\">",
"     \"Definition, etiology, and evaluation of precocious puberty\", section on 'McCune-Albright syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809063\">",
"    <span class=\"h2\">",
"     Familial male-limited precocious puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Boys with familial male-limited precocious puberty, also called familial GIPP or familial testotoxicosis, have been treated with a combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"     spironolactone",
"    </a>",
"    (which inhibits androgen action) and testolactone (which blocks the conversion of androgen to estrogen) (",
"    <a class=\"graphic graphic_figure graphicRef62460 \" href=\"UTD.htm?40/33/41502\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Testolactone may interfere with androgen assays and falsely elevate measured serum testosterone levels.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/10/34976?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    , an inhibitor of androgen synthesis, is also effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. It may lower cortisol levels and may be associated with hepatotoxicity.",
"   </p>",
"   <p>",
"    Either treatment option (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/10/34976?source=see_link\">",
"     ketoconazole",
"    </a>",
"    or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"      spironolactone",
"     </a>",
"     /testolactone)",
"    </span>",
"    in combination with a GnRH agonist can normalize the growth rate over the long term, but benefits to adult height have not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/44,47\">",
"     44,47",
"    </a>",
"    ]. Secondary GDPP may develop in the course of this treatment and is treated with GnRH agonist therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/2,48\">",
"     2,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case report of two boys with familial male-limited precocious puberty, a regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    (a highly selective nonsteroidal antiandrogen) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    (a third-generation aromatase inhibitor) was effective in reducing height velocity and decreasing secondary sexual characteristics without serious adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/49\">",
"     49",
"    </a>",
"    ]. In an open-label study in 14 boys, the same combination effectively reduced height velocity and bone maturation; gynecomastia and breast tenderness were the most common side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4889/abstract/50\">",
"     50",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809070\">",
"    <span class=\"h1\">",
"     INCOMPLETE PRECOCIOUS PUBERTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with idiopathic isolated premature thelarche or premature adrenarche need no therapy but should be reexamined regularly. In children with either variant, serial examinations serve to establish the diagnosis and to confirm that the initial physical development does not progress to more complete GDPP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H13#H13\">",
"     \"Definition, etiology, and evaluation of precocious puberty\", section on 'Types of incomplete precocious puberty'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/58/31650?source=see_link\">",
"       \"Patient information: Early puberty (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23809077\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The etiology of precocious puberty is classified by the underlying pathogenesis into three categories: gonadotropin-dependent precocious puberty (GDPP, also known as central precocious puberty), gonadotropin-independent precocious puberty (GIPP, also known as peripheral precocious puberty), and incomplete precocious puberty (",
"      <a class=\"graphic graphic_table graphicRef52565 graphicRef59268 graphicRef72054 \" href=\"UTD.htm?32/36/33358\">",
"       table 1A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23808232\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary goal of treatment for GDPP is to allow a child to grow to a normal adult height. For patients with idiopathic GDPP, the decision about whether to treat depends on the rate of sexual maturation and the estimated adult height as determined by the rate of bone age advancement (",
"      <a class=\"graphic graphic_table graphicRef72017 \" href=\"UTD.htm?40/24/41356\">",
"       table 2",
"      </a>",
"      ). Some forms of GDPP are slowly progressive and do not require treatment. (See",
"      <a class=\"local\" href=\"#H23809000\">",
"       'Decision to treat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If treatment for GDPP is indicated, we recommend treatment with a gonadotropin-releasing hormone (GnRH) agonist (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For children with progressive GDPP, younger age at initiation of therapy is associated with greater height benefits. (See",
"      <a class=\"local\" href=\"#H23809014\">",
"       'Effects on height'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clinically significant increments in height potential are achieved with a variety of GnRH agonists, and outcomes data are insufficient to recommend one form over another; several preparations are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef72979 \" href=\"UTD.htm?41/16/42252\">",
"       table 4",
"      </a>",
"      ). The choice of GnRH agonist formulation depends on patient and clinician preference and local regulatory approvals; in our practice we use",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/61/25558?source=see_link\">",
"       leuprolide",
"      </a>",
"      depot given intramuscularly (IM) once monthly. (See",
"      <a class=\"local\" href=\"#H23809021\">",
"       'Formulations and dosing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23809042\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During treatment with a GnRH agonist, patients should be monitored periodically for pubertal development and growth and bone age to determine whether the GnRH dose is adequate. In our practice, we also monitor GnRH efficacy by measuring concentrations of luteinizing hormone (LH) or sex steroids one to two months after initiation of therapy or change in dose. (See",
"      <a class=\"local\" href=\"#H23809028\">",
"       'Monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23809042\">",
"       'Our approach'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gonadotropin-independent precocious puberty (GIPP) is caused by peripheral secretion of sex hormones either from the gonads or adrenal glands, ectopic hCG production by a germ cell tumor, or by exogenous sources of sex steroids, and is independent from the hypothalamic-pituitary-gonadal axis. Causes of GIPP are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef59268 \" href=\"UTD.htm?38/57/39837\">",
"       table 1B",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      Treatment for GIPP is directed at the underlying pathology or removal of any exogenous exposure, as described in the table; these patients do not respond to GnRH agonist therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H9#H9\">",
"       \"Definition, etiology, and evaluation of precocious puberty\", section on 'Causes of gonadotropin independent precocious puberty (GIPP)'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H23809049\">",
"       'Treatment for GIPP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Incomplete precocious puberty consists of isolated breast development (premature thelarche) or isolated characteristics such as pubic hair development mediated by androgens produced in the adrenal glands (premature adrenarche). Either of these patterns usually is a variant of normal puberty and requires no intervention. However, a percentage of these patients will develop precocious puberty, so they should be followed closely. (See",
"      <a class=\"local\" href=\"#H23809070\">",
"       'Incomplete precocious puberty'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/1\">",
"      Mahachoklertwattana P, Kaplan SL, Grumbach MM. The luteinizing hormone-releasing hormone-secreting hypothalamic hamartoma is a congenital malformation: natural history. J Clin Endocrinol Metab 1993; 77:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/2\">",
"      Haddad N, Eugster E. An update on the treatment of precocious puberty in McCune-Albright syndrome and testotoxicosis. J Pediatr Endocrinol Metab 2007; 20:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/3\">",
"      Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009; 123:e752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/4\">",
"      Carel JC, L&eacute;ger J. Clinical practice. Precocious puberty. N Engl J Med 2008; 358:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/5\">",
"      Bar A, Linder B, Sobel EH, et al. Bayley-Pinneau method of height prediction in girls with central precocious puberty: correlation with adult height. J Pediatr 1995; 126:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/6\">",
"      Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999; 84:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/7\">",
"      Fontoura M, Brauner R, Prevot C, Rappaport R. Precocious puberty in girls: early diagnosis of a slowly progressing variant. Arch Dis Child 1989; 64:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/8\">",
"      Lazar L, Pertzelan A, Weintrob N, et al. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab 2001; 86:4127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/9\">",
"      Mul D, Bertelloni S, Carel JC, et al. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res 2002; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/10\">",
"      Klein KO, Barnes KM, Jones JV, et al. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001; 86:4711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/11\">",
"      Comite F, Cutler GB Jr, Rivier J, et al. Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report. N Engl J Med 1981; 305:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/12\">",
"      Crowley WF Jr, Comite F, Vale W, et al. Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981; 52:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/13\">",
"      Comite F, Cassorla F, Barnes KM, et al. Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted height. JAMA 1986; 255:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/14\">",
"      Rosenfield RL. Selection of children with precocious puberty for treatment with gonadotropin releasing hormone analogs. J Pediatr 1994; 124:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/15\">",
"      Pasquino AM, Pucarelli I, Segni M, et al. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. J Clin Endocrinol Metab 1999; 84:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/16\">",
"      Walvoord EC, Pescovitz OH. Combined use of growth hormone and gonadotropin-releasing hormone analogues in precocious puberty: theoretic and practical considerations. Pediatrics 1999; 104:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/17\">",
"      Tanaka T, Niimi H, Matsuo N, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab 2005; 90:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/18\">",
"      Badaru A, Wilson DM, Bachrach LK, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006; 91:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/19\">",
"      Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr 2011; 159:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/20\">",
"      Carel JC, Blumberg J, Seymour C, et al. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006; 154:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/21\">",
"      Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007; 92:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/22\">",
"      Rahhal S, Clarke WL, Kletter GB, et al. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol 2009; 2009:812517.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis KA, Eugster EA. Continual suppression by the histrelin implant for the treatment of central precocious puberty when left in place for two years. Abstract presented at the annual meeting of the Pediatric Academic Societies and Asian Society for Pediatric Research, Denver, May 2, 2011. (Abstract 3285.1).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/24\">",
"      Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev 1986; 7:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/25\">",
"      Wierman ME, Beardsworth DE, Crawford JD, et al. Adrenarche and skeletal maturation during luteinizing hormone releasing hormone analogue suppression of gonadarche. J Clin Invest 1986; 77:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/26\">",
"      Kunz GJ, Sherman TI, Klein KO. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment? J Pediatr Endocrinol Metab 2007; 20:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/27\">",
"      Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 2002; 109:E30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/28\">",
"      Demirbilek H, Alikasifoglu A, Gonc NE, et al. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection. Clin Endocrinol (Oxf) 2012; 76:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/29\">",
"      Neely EK, Lee PA, Bloch CA, et al. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010; 2010:398639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/30\">",
"      Lewis KA, Eugster EA. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty. J Pediatr 2013; 162:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/31\">",
"      Park HK, Lee HS, Ko JH, et al. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin Endocrinol (Oxf) 2012; 77:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/32\">",
"      Cassio A, Bal MO, Orsini LF, et al. Reproductive outcome in patients treated and not treated for idiopathic early puberty: long-term results of a randomized trial in adults. J Pediatr 2006; 149:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/33\">",
"      Palmert MR, Mansfield MJ, Crowley WF Jr, et al. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999; 84:4480.",
"     </a>",
"    </li>",
"    <li>",
"     Lee PA, Kerrigan JR. Precocious Puberty. In: Pediatric Endocrinology, Pescovitz OH, Eugster EA.  (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.329.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/35\">",
"      Feuillan PP, Foster CM, Pescovitz OH, et al. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med 1986; 315:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/36\">",
"      Feuillan PP, Jones J, Cutler GB Jr. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993; 77:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/37\">",
"      Nunez SB, Calis K, Cutler GB Jr, et al. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 2003; 88:5730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/38\">",
"      Feuillan P, Calis K, Hill S, et al. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab 2007; 92:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/39\">",
"      Shulman DI, Francis GL, Palmert MR, et al. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics 2008; 121:e975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/40\">",
"      Mieszczak J, Lowe ES, Plourde P, Eugster EA. The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 2008; 93:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/41\">",
"      Eugster EA, Rubin SD, Reiter EO, et al. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003; 143:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/42\">",
"      Holland FJ, Fishman L, Bailey JD, Fazekas AT. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Engl J Med 1985; 312:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/43\">",
"      Laue L, Kenigsberg D, Pescovitz OH, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989; 320:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/44\">",
"      Leschek EW, Jones J, Barnes KM, et al. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999; 84:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/45\">",
"      Ib&aacute;&ntilde;ez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche--normal variant or forerunner of adult disease? Endocr Rev 2000; 21:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/46\">",
"      Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf) 2008; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/47\">",
"      Soriano-Guill&eacute;n L, Lahlou N, Chauvet G, et al. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J Clin Endocrinol Metab 2005; 90:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/48\">",
"      Holland FJ, Kirsch SE, Selby R. Gonadotropin-independent precocious puberty (\"testotoxicosis\"): influence of maturational status on response to ketoconazole. J Clin Endocrinol Metab 1987; 64:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/49\">",
"      Kreher NC, Pescovitz OH, Delameter P, et al. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr 2006; 149:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4889/abstract/50\">",
"      Reiter EO, Mauras N, McCormick K, et al. Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). J Pediatr Endocrinol Metab 2010; 23:999.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16318 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-5480875BC6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4889=[""].join("\n");
var outline_f4_49_4889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23809077\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23810861\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23808232\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23808992\">",
"      TREATMENT FOR GDPP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23809000\">",
"      Decision to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23809007\">",
"      GnRH agonist treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23809014\">",
"      - Effects on height",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23809021\">",
"      - Formulations and dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23809028\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23809035\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23809042\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23809049\">",
"      TREATMENT FOR GIPP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7811799\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23809056\">",
"      McCune-Albright syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23809063\">",
"      Familial male-limited precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23809070\">",
"      INCOMPLETE PRECOCIOUS PUBERTY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23809077\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/16318\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16318|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/38/29283\" title=\"figure 1A\">",
"      Pubertal events girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/1/44048\" title=\"figure 1B\">",
"      Pubertal events boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/33/41502\" title=\"figure 2\">",
"      Rx precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16318|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/47/42747\" title=\"table 1A\">",
"      Evaluation of gonadotropin-dependent precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/57/39837\" title=\"table 1B\">",
"      Evaluation of gonadotropin-independent precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/53/42843\" title=\"table 1C\">",
"      Evaluation of incomplete precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/24/41356\" title=\"table 2\">",
"      Nonprogressive versus progressive precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/1/8220\" title=\"table 3\">",
"      Sexual maturity rating of secondary sexual characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/16/42252\" title=\"table 4\">",
"      GnRH agonists for GDPP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=related_link\">",
"      Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/58/31650?source=related_link\">",
"      Patient information: Early puberty (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_49_4890="Clinical manifestations and diagnosis of gout";
var content_f4_49_4890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of gout",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/49/4890/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4890/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/49/4890/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4890/contributors\">",
"     H Ralph Schumacher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/49/4890/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/49/4890/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/49/4890/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gout (monosodium urate crystal deposition disease) is characterized biochemically by extracellular fluid urate saturation. The clinical manifestations include one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent attacks of acute inflammatory arthritis",
"     </li>",
"     <li>",
"      Chronic arthropathy",
"     </li>",
"     <li>",
"      Accumulation of urate crystals in the form of tophaceous deposits",
"     </li>",
"     <li>",
"      Uric acid nephrolithiasis",
"     </li>",
"     <li>",
"      A chronic nephropathy that in gouty patients is most often due to comorbid states",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients with gout have hyperuricemia (saturation of serum for urate) at some point in their disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24230?source=see_link\">",
"     \"Uric acid balance\"",
"    </a>",
"    .) However, most hyperuricemic individuals never experience a clinical event resulting from urate crystal deposition. Thus, the diagnosis of gout focuses on the fundamental pathophysiologic events defining the clinical state: tissue deposition of urate crystals and the accompanying inflammatory and potentially destructive consequences. Within this framework, hyperuricemia is viewed as a necessary but not sufficient precondition for the development of urate crystal deposition disease and is to be distinguished from gout, the clinical syndrome.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of gout will be reviewed here. Issues related to asymptomatic hyperuricemia, the treatment of acute gout, and prevention of recurrent gout are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=see_link\">",
"     \"Treatment of acute gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"     \"Prevention of recurrent gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Descriptions of the epidemiology, clinical features, and natural history of gout evolved over more than two millennia of observations and study. The last half of the twentieth century produced confirmation that the pathogenesis of gout involves urate crystal deposition. Pivotal in this progress was the introduction of polarized light microscopy into clinical practice, providing urate crystal identification in synovial fluid as the means to achieve rapid and definitive diagnosis and to resolve the formerly ambiguous relationship between hyperuricemia and gout [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies over the past few decades have increased understanding of the molecular pathophysiology of gouty inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28344?source=see_link\">",
"     \"Pathophysiology of gouty arthritis\"",
"    </a>",
"    .) Finally, the development of drugs capable of suppressing gouty inflammation and hyperuricemia has provided the clinician with the means to prevent, and even reverse, the previously ravaging effects of acute inflammatory and chronic destructive manifestations of urate crystal deposition.",
"   </p>",
"   <p>",
"    Although these advances have favorably influenced the course of gout in the majority of affected individuals, the disorder persists as a problem [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/2\">",
"     2",
"    </a>",
"    ], often with less than optimal clinical outcomes despite attempts at treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/3\">",
"     3",
"    </a>",
"    ]. This is particularly true among nonadherent or poorly instructed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] and patients who do not fit what may have been considered \"classic\" clinical profile of the gouty patient (that is, a 30- to 60-year-old man who is likely to be obese, hypertensive, and a frequent imbiber of alcohol). These other at-risk groups differ from the classic profile in terms of age, involvement of women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], and concurrent illnesses and therapies (eg, diuretics and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=see_link\">",
"     \"Diuretic-induced hyperuricemia and gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3303?source=see_link\">",
"     \"Hyperuricemia and gout in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estimates of the prevalence of gout in the United States range from less than 3 million [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/11\">",
"     11",
"    </a>",
"    ] to 8 million or more individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]; both the incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/14,15\">",
"     14,15",
"    </a>",
"    ] and prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] of the disease appear to be increasing in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/13\">",
"     13",
"    </a>",
"    ] and worldwide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent hyperuricemia is a common biochemical abnormality that results from excessive urate production",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diminished renal uric acid excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24230?source=see_link\">",
"     \"Uric acid balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent hyperuricemia can be divided into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary hyperuricemia, which usually lasts indefinitely, describes urate saturation arising in the absence of coexisting diseases or drugs that alter uric acid production or excretion.",
"     </li>",
"     <li>",
"      Secondary hyperuricemia refers to excessive urate production (",
"      <a class=\"graphic graphic_table graphicRef80891 \" href=\"UTD.htm?5/49/5916\">",
"       table 1",
"      </a>",
"      ) or diminished renal clearance (",
"      <a class=\"graphic graphic_table graphicRef66799 \" href=\"UTD.htm?43/14/44267\">",
"       table 2",
"      </a>",
"      ) that is the result of another disease, drug, dietary product, or toxin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three classic stages in the natural history of progressive urate crystal deposition disease (gout) are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute gouty arthritis",
"     </li>",
"     <li>",
"      Intercritical (or interval) gout",
"     </li>",
"     <li>",
"      Chronic recurrent and tophaceous gout",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may be worthwhile to regard the stages of gout as emerging sequentially, with clinical severity often paralleling the frequency of acute gout flares and, ultimately, the development of chronic gouty arthropathy and tophaceous gout. In this context, treatment with antihyperuricemic (urate-lowering) agents is not curative, but it may reset the course of the individual patient and provide what is essentially a cure if therapy is maintained.",
"   </p>",
"   <p>",
"    With current effective therapies, progression of gout to the chronic tophaceous stage is now less frequent among the majority of compliant patients with primary gout and among most patients with secondary gout [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/18\">",
"     18",
"    </a>",
"    ]. When progression does occur, it is most often among noncompliant patients, those in whom the management scheme has not been appropriately communicated, and those in whom the diagnosis of gout has not been made. Other patients liable to show progression of gout include those intolerant of or treated with inadequate doses of urate-lowering agents, those receiving medications (usually for comorbidities) that interfere with urate-lowering agents, and organ transplant recipients.",
"   </p>",
"   <p>",
"    These considerations differ from those associated with the manifestations of acute hyperuricemia (primarily acute renal failure) seen in the tumor-lysis syndrome or with other causes of massive tissue breakdown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link&amp;anchor=H2#H2\">",
"     \"Uric acid renal diseases\", section on 'Acute uric acid nephropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ACUTE GOUTY ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute gouty arthritis usually occurs after years of asymptomatic hyperuricemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Typical attack",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical attack of acute gouty arthritis, which is intensely inflammatory, includes the following clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe pain, redness, swelling, and disability. Maximal severity of the attack is usually reached within 12 to 24 hours. Complete resolution of the earliest attacks almost always occurs within a few days to several weeks, even in untreated individuals.",
"     </li>",
"     <li>",
"      Lower extremity involvement. At least 80 percent of initial attacks involve a single joint, most often at the base of the great toe (first metatarsophalangeal joint, known as podagra) or the knee.",
"     </li>",
"     <li>",
"      Signs of inflammation extending beyond the confines of the joint that is primarily involved. This feature may give the impression of arthritis in several contiguous joints or of tenosynovitis, dactylitis (sausage digit), or even cellulitis.",
"     </li>",
"     <li>",
"      Involvement in an ankle or instep or in a wrist, finger, or olecranon bursa, which can occur initially but is more common in a recurrent episode of gouty arthritis. Other potential sites of involvement include other bursas, shoulders, hips, sternoclavicular joints, spine, and sacroiliac joints, which may cause diagnostic confusion.",
"     </li>",
"     <li>",
"      More subtle inflammatory episodes, which appear to occur in some patients. However, these have not been well-studied.",
"     </li>",
"     <li>",
"      Inconstant or nonspecific laboratory abnormalities. Neutrophilic leukocytosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevation of the erythrocyte sedimentation rate or C-reactive protein are common in acute gout attacks, but their presence in other acute arthritides generally makes these findings of little diagnostic value. An exception to this may be in distinguishing gout from events such as stress fracture, which may cause some of the above symptoms and physical findings in the absence of laboratory abnormalities and which can be confirmed by imaging studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of stress fractures\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum uric acid (sUA) levels can be difficult to interpret during an acute gout flare. For example, in the early months of urate-lowering drug therapy, gout attacks often occur with normal or even low serum urate concentrations at the time of the acute event. Lower urate levels have also been proposed to result from effects of cytokines during flares. Overall, normal to low serum urate values have been noted in 12 to 43 percent of patients with acute episodes of gout [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. In patients suspected of gout based upon the features noted above, an elevated sUA (&ge;6.8",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    can lend support to the diagnosis but is not diagnostic. The most accurate time for assessment of sUA (and establishment of a baseline value) is two weeks or more after complete subsidence of an acute gout flare.",
"   </p>",
"   <p>",
"    The initiation of urate-lowering therapy, although protective in the long term, can precipitate acute gouty arthritis. As a result, prophylaxis is usually given to prevent this complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link&amp;anchor=H24#H24\">",
"     \"Prevention of recurrent gout\", section on 'Prophylaxis during initiation of antihyperuricemic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous circumstances promote or are associated with acute attacks of gouty arthritis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trauma, surgery, starvation, fatty foods and other dietary overindulgence, dehydration, and ingestion of drugs affecting (raising or lowering) serum urate concentrations (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      , uricosuric agents, thiazide, or loop diuretics) and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      may all promote gouty attacks. In men, increasing alcohol consumption (beer and spirits, but not wine) is associated with a proportionately greater risk of developing gout [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/23\">",
"       23",
"      </a>",
"      ]. Each of these circumstances may provoke generalized disturbances in extracellular fluid urate concentrations or may affect crystals in the inflammatory milieu [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High levels of meat and seafood consumption are associated with higher serum urate concentrations, while increased intake of low-fat dairy products correlates with lower urate levels [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/25\">",
"       25",
"      </a>",
"      ]. The amounts of meat and seafood in the diet are significantly associated with an increased risk of developing gouty arthritis. This was illustrated in a prospective study of 47,150 male health professionals [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/26\">",
"       26",
"      </a>",
"      ]. Those in the highest quintile of meat consumption had an adjusted hazard ratio (HR) of 1.41 compared with the lowest quintile; those consuming the largest amount of fish had a HR of 1.51. Neither the intake of purine-rich vegetables nor total protein intake was associated with an increased risk of gout.",
"      <br/>",
"      <br/>",
"      On the other hand, the highest quintile of dairy product consumption was associated with a significant reduction in risk (HR of 0.56) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/26\">",
"       26",
"      </a>",
"      ]. In a separate report, higher coffee consumption was also associated with a lower risk of acute gout [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/27\">",
"       27",
"      </a>",
"      ]. Coffee, but not tea, consumption reduced the risk of having hyperuricemia, suggesting that the uric acid lowering effect is not due to caffeine but to other, as yet unidentified, components of coffee [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Locally elevated urate concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/29\">",
"       29",
"      </a>",
"      ], in conjunction with repeated joint microtrauma, prior degenerative change, or reduced temperature in poorly perfused distal tissues [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/30\">",
"       30",
"      </a>",
"      ], may predispose individual joints to gouty inflammation.",
"     </li>",
"     <li>",
"      Osteoarthritic changes in interphalangeal joints (Heberden's and Bouchard's nodes) may predispose these joints to develop coexisting gouty arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/31,32\">",
"       31,32",
"      </a>",
"      ], particularly in older individuals with chronic kidney disease or in those receiving diuretic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=see_link\">",
"       \"Diuretic-induced hyperuricemia and gout\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute polyarticular gout",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarticular gouty arthritis is the initial manifestation in less than 20 percent of patients with gout but occurs with increasing frequency in later flares. Polyarticular symptoms are particularly common late in the course of untreated gout, when multiple recurrences, short or absent symptom-free intervals, and palpable tophaceous deposits are common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=see_link\">",
"     \"Evaluation of the adult with polyarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A polyarticular initial presentation of gouty arthritis may be more frequent in patients in whom hyperuricemia and gout arise secondary to a myeloproliferative or lymphoproliferative disorder or in organ transplant recipients who are receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3303?source=see_link\">",
"     \"Hyperuricemia and gout in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis of acute gout",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis should be sought when acute gout is suspected, both to exclude alternative explanations for the acute event and to ensure that long-term, expensive, and potentially toxic urate-lowering medications are not prescribed unnecessarily if there is recurrence or progression of the arthritis.",
"   </p>",
"   <p>",
"    The diagnosis of acute gout is most secure when supported by visualization of urate crystals by experienced examiners in a sample of fluid aspirated from an affected joint (or bursa). If crystal confirmation of the diagnosis cannot be made, a provisional diagnosis may be made on the basis of clinical data, including history, physical examination, appropriate laboratory tests, and, increasingly, imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Polarizing microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial fluid obtained from joints or bursas (as well as material aspirated from tophaceous deposits, if any) may be directly examined using compensated polarized light microscopy (",
"    <a class=\"graphic graphic_picture graphicRef85631 graphicRef85632 graphicRef85633 \" href=\"UTD.htm?24/53/25433\">",
"     picture 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During an acute gouty episode, aspiration of the affected joint and polarized compensated light microscopy of synovial fluid permit detection of intracellular monosodium urate crystals in synovial fluid. The sensitivity of this technique in demonstrating negatively birefringent crystals in patients with acute gouty arthritis is at least 85 percent, and the specificity for gout is 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. However, acute gouty arthritis may occasionally coexist with another type of joint disease, such as septic arthritis or pseudogout.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity of the joint fluid analysis can be improved by examination of the sediment in a centrifuged specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/35\">",
"     35",
"    </a>",
"    ]. Additional approaches to consider in the event of a negative (no urate crystals seen) study during the acute attack include aspiration of a concurrently inflamed joint or (less helpful in ruling out an accompanying cause for the acute event) aspiration of an uninflamed but previously involved joint or of a tophus, if either is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Criteria for clinical diagnosis of gout",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of the means to identify urate crystals or in the presence of a negative polarized light microscopic study, a tentative diagnosis of gout may be made by a combination [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/36\">",
"     36",
"    </a>",
"    ] of clinical and historical criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/33,35,37,38\">",
"     33,35,37,38",
"    </a>",
"    ]. This method of diagnosis must be regarded as provisional and as much less specific [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/37\">",
"     37",
"    </a>",
"    ]. Clinical, imaging, and laboratory criteria that may be useful include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A classic history of one or more episodes of monoarticular arthritis followed by intercritical period(s) completely free of symptoms",
"     </li>",
"     <li>",
"      Maximum inflammation (with the features described above) within 24 hours",
"     </li>",
"     <li>",
"      Unilateral first metatarsophalangeal joint attack (podagra)",
"     </li>",
"     <li>",
"      Presence of a visible or palpable lesion, which by location or appearance is likely to be a tophus",
"     </li>",
"     <li>",
"      Hyperuricemia",
"     </li>",
"     <li>",
"      Subcortical bone cysts apparent on plain radiograph or magnetic resonance imaging (MRI) examination identifying gouty tophi or erosions. Changes of these types seen in imaging procedures are not usually detectable at the time of the first acute attack of gouty arthritis.",
"     </li>",
"     <li>",
"      Dual-energy computerized tomography (CT) examination identifying urate deposits. Several studies have shown that urates can be specifically identified in articular and periarticular locations and can be distinguished from calcium deposition using dual-energy CT [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/39-41\">",
"       39-41",
"      </a>",
"      ]. Further studies are needed to determine the frequency of identifiable deposits in early disease and the clinical utility of this approach, which may be of future benefit in patients in whom the diagnosis remains uncertain despite standard clinical evaluation.",
"     </li>",
"     <li>",
"      Ultrasound examination showing either a linear density overlying the cartilage or tophaceous appearing deposits [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/42\">",
"       42",
"      </a>",
"      ]. In studies of patients with a clinical suspicion or proven diagnosis of gout, the ultrasound finding of hyperechoic cloudy areas (HCA) had a sensitivity and specificity for gout of 79 and 95 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/43\">",
"       43",
"      </a>",
"      ], while the double contour sign (DCS) from hyperechoic enhancement overlying the cartilage surface had a sensitivity and specificity of 44 and 99 percent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef85635 \" href=\"UTD.htm?34/42/35503\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/44\">",
"       44",
"      </a>",
"      ]. In patients with asymptomatic hyperuricemia in a small pilot study, both HCA and DCS were found in the joints of some patients who had never had symptoms of gouty arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/45\">",
"       45",
"      </a>",
"      ]. The implications of this latter study with regard to making a diagnosis of gout in patients without symptoms of the disease await further discussion and confirmation of the findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The accuracy of clinical diagnosis without crystal confirmation is uncertain. A study of 30 patients with crystal proven gout showed that the presence of two of three of the Rome criteria (serum uric acid greater than 7",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    presence of tophi; or painful joint swelling of abrupt onset and clearing within one to two weeks) had a 77 percent positive predictive value. No clinical criteria were more than 70 percent sensitive or 89 percent specific [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An appropriate clinical picture and an elevated serum urate concentration suggest the diagnosis of acute gouty arthritis. However, as noted above, an appreciable number of flares occur in patients who, at the time of the attack, have normal or even low serum urate concentrations. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Typical attack'",
"    </a>",
"    above.) Conversely, patients with acute arthritis due to causes other than gout may have coincidental hyperuricemia.",
"   </p>",
"   <p>",
"    A diagnostic approach has been proposed to improve the accuracy of diagnoses made without joint fluid analysis, which incorporates many of the features described above. The rule was based upon an analysis of 328 patients with monoarthritis seen initially by family practitioners in the Netherlands; the patients also underwent prompt expert synovial fluid analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/38\">",
"     38",
"    </a>",
"    ]. The model used seven variables, which were assigned weighted scores that could be ascertained in primary care to distinguish three levels of risk for gout. The following variables and scoring values were used:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Male sex (2 points)",
"     </li>",
"     <li>",
"      Previous patient-reported arthritis attack (2 points)",
"     </li>",
"     <li>",
"      Onset within one day (0.5 points)",
"     </li>",
"     <li>",
"      Joint redness (1 point)",
"     </li>",
"     <li>",
"      First metatarsal phalangeal joint involvement (2.5 points)",
"     </li>",
"     <li>",
"      Hypertension or at least one cardiovascular disease (1.5 points)",
"     </li>",
"     <li>",
"      Serum uric acid level greater than 5.88",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.5 points)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the study cohort, scoring for low (&le;4 points), intermediate (&gt;4 to &lt;8 points), and high (&ge;8 points) probability of gout identified groups with a prevalence of gout of 2.2, 31.2, and 82.5 percent, respectively. This approach yielded substantially fewer false positive diagnoses than those made clinically by the family practitioners (17 versus 36 percent). Patients falling into the intermediate category would most benefit from further evaluation with synovial fluid analysis. This rule was applied only to patients with monoarthritis and requires external validation in another primary care setting. For ease of use, the authors of the study have provided an online calculator that provides an absolute calculated risk at",
"    <a class=\"external\" href=\"file://www.umcn.nl/Research/Departments/eerstelijnsgeneeskunde/Pages/Jichtcalculator.aspx\">",
"     www.umcn.nl/Research/Departments/eerstelijnsgeneeskunde/Pages/Jichtcalculator.aspx",
"    </a>",
"    (accessed November 29, 2010).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resolution of the acute gouty attack is sometimes accompanied by desquamation of the skin overlying the affected joint. The physiologic basis of the resolution of acute gouty inflammation is complex but centers on attenuation of a number of pathogenetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28344?source=see_link\">",
"     \"Pathophysiology of gouty arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3404322\">",
"    <span class=\"h2\">",
"     Differential diagnosis of acute gouty arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other conditions may mimic acute gouty arthritis. Aspiration of synovial fluid from the affected joint and analysis of the fluid by Gram stain, culture, and regular and polarized light microscopy permit the distinction of gout from the disorders below in the great majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/34,47\">",
"     34,47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnosis of acute gout'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The differential diagnosis of acute monoarticular gouty arthritis includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Septic arthritis &mdash; Acute monoarticular gout can give a clinical picture indistinguishable from acute septic arthritis, including fever, leukocytosis, and elevated erythrocyte sedimentation rate. On rare occasions, acute gout and septic arthritis coexist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"       \"Septic arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trauma &mdash; Gouty attacks of lesser severity may be mimicked by a stress fracture or traumatic process in the bone or joint.",
"     </li>",
"     <li>",
"      Pseudogout &mdash; Features that help to differentiate between gout and pseudogout are illustrated in the table (",
"      <a class=\"graphic graphic_table graphicRef65326 \" href=\"UTD.htm?35/0/35852\">",
"       table 3",
"      </a>",
"      ). In some cases, both urate and CPPD crystals are identified in the synovial fluid neutrophils in patients in whom these disorders coexist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"       \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other crystalline arthritides &mdash; Arthritis or periarthritis due to the deposition of basic calcium phosphate crystals cannot usually be diagnosed with certainty by polarized microscopy because the individual crystals are below the resolution of standard light microscopy and because clumps of crystal aggregates are not birefringent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/48\">",
"       48",
"      </a>",
"      ]. In this setting, transmission electron microscopy and x-ray powder diffraction have been successfully used for research identification of these crystals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"       \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other &mdash; The differential diagnosis among patients with a history of recurrent attacks with spontaneous resolution or rapid and complete improvement with use of nonsteroidal antiinflammatory drugs includes reactive arthritis, palindromic rheumatism, and acute rheumatic fever, in addition to pseudogout. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features of rheumatoid arthritis\", section on 'Palindromic rheumatism'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While many clinicians are skilled at joint aspiration, those who are not may request the assistance of an orthopedic surgeon to obtain the fluid or of a rheumatologist to perform a joint tap and to help with the analysis of the synovial fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INTERCRITICAL GOUT AND RECURRENT GOUTY ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon resolution of an acute attack of gout, the patient is said to have entered an intercritical (between attacks) period. Even after severe and incapacitating acute attacks, intercritical periods early in the course of gout are most often entirely asymptomatic. This sequence is so uncommon in arthritic disorders, other than crystal deposition diseases and palindromic rheumatism, that its presence is highly suggestive of the diagnosis.",
"   </p>",
"   <p>",
"    Intervals between attacks of acute gouty arthritis are of variable duration. Most untreated patients with gout will experience a second episode within two years. As an example, one large group of patients studied prior to effective antihyperuricemic (urate-lowering) therapy found that 62 percent of patients had a second attack within the first year, 78 percent within two years, and 93 percent within 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/49\">",
"     49",
"    </a>",
"    ]. The trend among untreated patients is toward recurrent acute attacks that occur after progressively shorter asymptomatic periods and that are increasingly prolonged and disabling, polyarticular, and associated with fever.",
"   </p>",
"   <p>",
"    Polyarticular flares of gouty arthritis may occur in a sequential (migratory) pattern or simultaneously or may involve a cluster of adjacent joints, tendons, and bursae. Bony erosions and deformities can develop (chronic gouty arthropathy), resulting in the disappearance of intercritical periods.",
"   </p>",
"   <p>",
"    This stage of chronic gouty arthropathy is often accompanied by tophaceous deposits that contribute to deformity and disability. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Chronic tophaceous gout'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of effective means to control hyperuricemia has led to substantial reductions in the rates of recurrence of gouty arthritis and of tophi in patients adherent to long-term urate-lowering therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/18\">",
"     18",
"    </a>",
"    ]. The initial intercritical period provides an excellent opportunity to do the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establish the diagnosis of gout if this has not been accomplished during the acute attack (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Diagnosis of intercritical or chronic tophaceous gout'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Identify and relieve reversible causes of hyperuricemia, potentially obviating the need for long term urate-lowering therapy",
"     </li>",
"     <li>",
"      Classify the patient with regard to the mechanism underlying hyperuricemia and gout, including the causes of secondary hyperuricemia due to overproduction or underexcretion (",
"      <a class=\"graphic graphic_table graphicRef80891 \" href=\"UTD.htm?5/49/5916\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66799 \" href=\"UTD.htm?43/14/44267\">",
"       table 2",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"       \"Asymptomatic hyperuricemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Institute prophylactic antiinflammatory and urate-lowering therapy, if indicated. The prevention of recurrent gout is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"       \"Prevention of recurrent gout\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluate the patient for and, if appropriate, initiate management of comorbidities common in gout patients (such as hypertension, chronic renal functional impairment, cardiovascular disease, and the components of the metabolic syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/50\">",
"       50",
"      </a>",
"      ]. In the context of these comorbidities, as well as for the aim of some degree of serum urate reduction, lifestyle changes should be reviewed with the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/23,25,26\">",
"       23,25,26",
"      </a>",
"      ]. These might include changes in dietary intake and composition, reduction of alcohol intake, reduction to ideal body weight, and dietary supplementation, such as with vitamin C. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"       \"Prevention of recurrent gout\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CHRONIC TOPHACEOUS GOUT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tophaceous gout is characterized by collections of solid urate in connective tissues (which may occasionally be calcified). While these collections may be apparent clinically or may be detected with plain radiography, dual energy computerized tomography (CT), ultrasonography, or magnetic resonance (MR) imaging, it is likely that many patients with gout and sustained hyperuricemia have a much larger burden of clinically inapparent urate crystal deposits than is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Clinical appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tophi are visible",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    palpable and can be present on the ears or in the soft tissues including articular structures or bursae (",
"    <a class=\"graphic graphic_picture graphicRef81692 \" href=\"UTD.htm?36/56/37775\">",
"     picture 2",
"    </a>",
"    ). Tophi are typically not painful or tender. They may attenuate the skin, revealing a yellow or white color. On the ear, they do not transilluminate. A chronic granulomatous inflammatory response is identifiable on histological examination of the lesions, and, on occasion, acute inflammation, mimicking that of gouty arthritis, occurs adjacent to one or several tophi (",
"    <a class=\"graphic graphic_picture graphicRef73021 \" href=\"UTD.htm?25/60/26575\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The inflammation may extend beyond the confines of a single joint, producing generalized enlargement of a digit due to the presence of tophi",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the inflammation itself. The appearance may be similar to dactylitis seen in other disorders, such as psoriatic arthritis, other spondyloarthropathies, and sarcoidosis. The expansive and destructive changes associated with tophaceous gout may be mistaken for osteomyelitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52500 \" href=\"UTD.htm?30/61/31710\">",
"     image 2",
"    </a>",
"    ) and have sometimes led to erroneous amputation of involved digits [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical picture of chronic tophaceous gout may be confused with other forms of chronic inflammatory polyarthritis such as rheumatoid arthritis (particularly if tophi are mistaken for rheumatoid nodules). In these circumstances, the asymmetry and asynchrony of joint involvement in gout, the presence of urate crystals in the nodular lesions, and the distinctive radiographic features will often suffice to distinguish between these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone erosions due to tophi may have characteristic delicate \"overhanging\" edges. The characteristics of tophi on magnetic resonance (MR) images include relatively homogeneous intermediate to low signal on T1-weighted images, as well as T2-weighted images that have variable signal intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/52\">",
"     52",
"    </a>",
"    ]. Either homogeneous or peripheral enhancement may occur with the addition of gadolinium. Tophus size can be estimated on MR imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/53\">",
"     53",
"    </a>",
"    ] or quantified by dual energy CT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/39\">",
"     39",
"    </a>",
"    ], but the clinical usefulness of such information is uncertain.",
"   </p>",
"   <p>",
"    Ultrasound examination directed to joints or soft tissue deposits is an increasingly promising modality for the early detection and monitoring of therapy for gout [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/42\">",
"     42",
"    </a>",
"    ]. Characteristic lines overlying the surface of joint cartilage can be very suggestive (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85635 \" href=\"UTD.htm?34/42/35503\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Criteria for clinical diagnosis of gout'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of effective urate-lowering treatment, the interval from the first gouty attack to the onset of chronic arthritis or detectable tophi averaged about 12 years, although intervals ranging from less than 5 years to 40 years were noted in individual patients.",
"   </p>",
"   <p>",
"    In the era preceding the availability of effective urate-lowering treatment, duration of gout and degree of hyperuricemia were correlated with the rate and extent of tophus formation. After 20 years of untreated gout, almost 75 percent of patients were affected, with the highest prevalence in patients with the highest serum urate concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the classic presentation, a number of reports have described patients with tophaceous deposits in the absence of, or prior to, gouty arthritis, a presentation that was previously considered a rare occurrence restricted to patients with uric acid overproduction due to myeloproliferative disorders or hereditary enzyme defects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Although this situation may, in part, reflect increasing recognition that tophi can form in any area containing connective tissue (including the meninges but not the brain and spinal cord), risk factors similar to those accounting for cryptic gout in older patients may contribute to tophus formation as the first sign of gout. Such patients are more likely to be women, to have predominant or exclusive involvement of the fingers, to have chronic kidney disease, and to be treated with a diuretic or antiinflammatory drug [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urate-lowering treatment of gout with uricosuric agents and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    initially led to a dramatic reduction in chronic gouty arthritis and tophaceous gout, with a prevalence of less than 5 percent reported in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/18\">",
"     18",
"    </a>",
"    ]. However, these progressive forms of gout are being seen more frequently once again in certain subgroups of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Residual prevalences of chronic polyarticular and tophaceous gout approaching 50 percent have been reported in some series of men with gout whose major risk factors were excessive alcohol consumption, diuretic use, and, most important, suboptimal management or poor patient compliance [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A more compliant group of older patients (most often women) is prone to develop polyarticular and tophaceous gout in osteoarthritic joints as illustrated by the following observations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one report, 8 of 60 patients with gout were older women (mean age 82 years), all of whom were receiving diuretic therapy; most had tophi in osteoarthritic interphalangeal joints [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second series, 17 percent of 149 patients with osteoarthritis had gout, often with low-grade inflammation, in osteoarthritic finger joints [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/32\">",
"       32",
"      </a>",
"      ]. These patients were older (mean age 71 years) and were evenly distributed in gender. Over 70 percent were receiving diuretics, 60 percent had impaired renal function, and the mean serum urate concentration was 11",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (654",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The triad of diuretic-induced hyperuricemia, renal insufficiency, and nodal osteoarthritis plus overrepresentation of women represents a distinctly different presentation from the classically described group of middle aged men with tophaceous gout who have a higher incidence of hypertension, obesity, and ethanol abuse.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organ transplant recipients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (and often diuretics as well) are at increased risk for the accelerated development of chronic tophaceous gout [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Both renal and cardiac transplant recipients, particularly those with compromised renal function, have developed severe and often difficult to manage complications of the hyperuricemic effect of cyclosporine, which is due to impaired urate excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3303?source=see_link\">",
"       \"Hyperuricemia and gout in renal transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other patients at increased risk for chronic tophaceous gout are those who have chronic kidney disease that has been felt to preclude full-dose antihyperuricemic drug therapy, those who are allergic to or intolerant of urate-lowering agents, and those receiving doses of urate-lowering agents that are inadequate to achieve goal serum urate levels in a range below the limit of urate solubility (often recommended as &lt;6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [357",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RENAL COMPLICATIONS OF CHRONIC HYPERURICEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major renal complications of chronic hyperuricemia: nephrolithiasis and chronic urate nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Nephrolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uric acid stones are a component of the morbidity suffered by patients with gout. Pure uric acid stones account for only 5 to 10 percent of all urinary tract stones in the United States and Europe but comprise 40 percent or more of stones in areas with hot, arid climates in which the tendency to a low urine volume and acid urine pH promote uric acid precipitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of uric acid stones among patients with gout prior to effective antihyperuricemic treatment was about 20 percent, several hundred-fold greater than that in the adult non-gouty population. Although many urinary tract calculi in patients with gout are composed entirely of uric acid, many more contain calcium oxalate or calcium phosphate surrounding a central nidus of uric acid.",
"   </p>",
"   <p>",
"    There are three major risk factors for uric acid nephrolithiasis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased uric acid excretion",
"     </li>",
"     <li>",
"      Reduced urine volume",
"     </li>",
"     <li>",
"      Low urine pH, a setting in which most of the uric acid exists as the un-ionized, more insoluble uric acid form rather than as the dissociated, more soluble urate anion form",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Chronic urate nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal impairment is common among patients with gout but usually reflects the coexistence of other disorders such as hypertension, diabetes mellitus, obesity, atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/50,58,59\">",
"     50,58,59",
"    </a>",
"    ], or, in some instances, lead intoxication resulting from use of unbonded whiskey (moonshine) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, urate crystals can deposit in the renal medullary interstitium, producing a chronic inflammatory (tophaceous) reaction and varying degrees of fibrosis. The clinical manifestations of what has been called chronic urate nephropathy are an elevated serum creatinine, a bland urine sediment, and hyperuricemia out of proportion to the degree of renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link&amp;anchor=H5#H5\">",
"     \"Uric acid renal diseases\", section on 'Chronic urate nephropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF INTERCRITICAL OR CHRONIC TOPHACEOUS GOUT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even during the asymptomatic intercritical period, urate crystals are identifiable in synovial fluid from previously affected joints in virtually all untreated gouty patients and in approximately 70 percent of those receiving uric acid-lowering therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. This allows late establishment of the diagnosis in the majority of patients in whom the diagnosis was not made in the acute setting.",
"   </p>",
"   <p>",
"    The high prevalence of urate crystals in aspirates from joints previously affected only once supports the view noted above that, in most instances, deposition of urate crystals in and about joints precedes the first clinical episode of gout by a substantial period of time.",
"   </p>",
"   <p>",
"    Demonstration of urate crystals in aspirates of tophaceous deposits provides a convenient and specific means to corroborate the diagnosis in the small proportion of gouty individuals with tophi [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Histologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, tissues that are being prepared for histologic examination for urate crystals should be examined as fresh or frozen sections or should be preserved in alcohol (rather than in formalin) and later stained with a nonaqueous system such as Wright-Giemsa stain. However, formalin fixed, paraffin embedded tissue has been reported to still occasionally have demonstrable birefringent urate crystals if stained with a nonaqueous technique using alcoholic eosin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/49/4890/abstract/67\">",
"     67",
"    </a>",
"    ]. Aqueous stains, such as hematoxylin and eosin, allow urate crystals to dissolve, leaving behind a nondiagnostic eosinophilic matrix that may have foreign body giant cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Criteria for clinical diagnosis of intercritical gout",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of the means to identify urate crystals or in the presence of a negative polarized light microscopic study, a provisional diagnosis of gout is made by a combination of clinical and historical criteria. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Criteria for clinical diagnosis of gout'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/3/11314?source=see_link\">",
"       \"Patient information: Gout (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=see_link\">",
"       \"Patient information: Gout (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111564623\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with gout have hyperuricemia (saturation of serum for urate) at some point in their disease. However, most hyperuricemic individuals never experience a clinical event resulting from urate crystal deposition. Persistent hyperuricemia is common, resulting from excessive urate production",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diminished renal uric acid excretion. It is termed either primary or secondary, based upon the absence or presence, respectively, of coexisting diseases or drugs, dietary products, or toxins that increase urate production (",
"      <a class=\"graphic graphic_table graphicRef80891 \" href=\"UTD.htm?5/49/5916\">",
"       table 1",
"      </a>",
"      ) or decrease urate excretion (",
"      <a class=\"graphic graphic_table graphicRef66799 \" href=\"UTD.htm?43/14/44267\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three stages in the natural history of progressive urate crystal deposition disease (gout) are acute gouty arthritis, intercritical (or interval) gout, and chronic recurrent and tophaceous gout. With current effective therapies, progression of gout to the chronic tophaceous stage is now less frequent among the majority of compliant patients with primary gout and among most patients with secondary gout. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute gouty arthritis usually occurs after years of asymptomatic hyperuricemia. Numerous circumstances promote or are associated with acute attacks, which are typically intensely inflammatory, with severe pain, redness, swelling, and disability. Maximal severity of the attack is usually reached within 12 to 24 hours. Complete resolution of the earliest attacks almost always occurs within a few days to several weeks, even in untreated individuals. Polyarticular gouty arthritis is the initial manifestation in less than 20 percent of patients with gout but occurs with increasing frequency in later flares. Gout sometimes occurs with normal or even low serum urate concentrations at the time of the acute event. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Predisposing factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Acute gouty arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Typical attack'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Acute polyarticular gout'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A definitive diagnosis should be sought when acute gout is suspected, both to exclude alternative explanations for the acute event and to ensure that long-term therapy is not prescribed unnecessarily. The diagnosis is most secure when supported by visualization of urate crystals by experienced examiners in a sample of fluid aspirated from an affected joint (or bursa). If crystal confirmation of the diagnosis cannot be made, a provisional diagnosis may be made on the basis of clinical data. The differential diagnosis includes septic arthritis, trauma, calcium pyrophosphate deposition (pseudogout), and other types of inflammatory arthritis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis of acute gout'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Polarizing microscopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Criteria for clinical diagnosis of gout'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3404322\">",
"       'Differential diagnosis of acute gouty arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upon resolution of an acute attack of gout, the patient is said to have entered an intercritical (between attacks) period, which is most often asymptomatic. This sequence is highly suggestive of the diagnosis. The trend without treatment is toward recurrent acute attacks that occur after progressively shorter asymptomatic periods and that are increasingly prolonged and disabling, polyarticular, and associated with fever. The initial intercritical period provides an opportunity to establish the diagnosis of gout if this has not been accomplished during the acute attack, to classify the patient with regard to the mechanism underlying hyperuricemia and gout, and to institute preventive and therapeutic interventions. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Intercritical gout and recurrent gouty arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tophaceous gout is characterized by collections of solid urate, which is occasionally calcified, in connective tissues. These collections can be visible",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      palpable but not painful or tender, and they can be present on the ears or in the soft tissues including articular structures, tendons, bursae, or bone (",
"      <a class=\"graphic graphic_picture graphicRef81692 \" href=\"UTD.htm?36/56/37775\">",
"       picture 2",
"      </a>",
"      ). Tophi may be detected with plain radiography, CT, ultrasonography, or magnetic resonance (MR) imaging; it is likely that many patients with gout and sustained hyperuricemia have a much larger burden of clinically inapparent urate crystal deposits than is suspected. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Chronic tophaceous gout'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Clinical appearance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Without effective urate-lowering treatment, duration of gout and degree of hyperuricemia are correlated with the rate and extent of tophus formation, with almost 75 percent of patients affected after 20 years of untreated gout. Urate-lowering treatment of gout led to a dramatic reduction in chronic gouty arthritis and tophaceous gout, but these forms of gout persist in inadequately treated patients, especially in certain patient subgroups (poorly adherent patients, organ transplant recipients, patients refractory to or intolerant of urate lowering therapeutic agents). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two major renal complications of chronic hyperuricemia: nephrolithiasis and chronic urate nephropathy. Renal impairment is common among patients with gout but usually reflects the coexistence of other disorders such as hypertension, diabetes mellitus, obesity, atherosclerosis, or, in some instances, lead intoxication resulting from use of unbonded whiskey (moonshine). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Renal complications of chronic hyperuricemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Nephrolithiasis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Chronic urate nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the asymptomatic intercritical period, extracellular urate crystals are identifiable in synovial fluid from previously affected joints in virtually all untreated gouty patients and in approximately 70 percent of those receiving uric acid-lowering therapy. This allows late establishment of the diagnosis in the majority of patients in whom the diagnosis was not made in the acute setting. Demonstration of urate crystals in aspirates of tophaceous deposits provides a convenient and specific means to corroborate the diagnosis in the small proportion of gouty individuals with tophi. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Diagnosis of intercritical or chronic tophaceous gout'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Histologic examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Criteria for clinical diagnosis of intercritical gout'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/1\">",
"      MCCARTY DJ, HOLLANDER JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/2\">",
"      Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/3\">",
"      Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol 2008; 20:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/4\">",
"      Nakayama DA, Barthelemy C, Carrera G, et al. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum 1984; 27:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/5\">",
"      Lawry GV 2nd, Fan PT, Bluestone R. Polyarticular versus monoarticular gout: a prospective, comparative analysis of clinical features. Medicine (Baltimore) 1988; 67:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/6\">",
"      Puig JG, Mich&aacute;n AD, Jim&eacute;nez ML, et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 1991; 151:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/7\">",
"      Lally EV, Ho G Jr, Kaplan SR. The clinical spectrum of gouty arthritis in women. Arch Intern Med 1986; 146:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/8\">",
"      Macfarlane DG, Dieppe PA. Diuretic-induced gout in elderly women. Br J Rheumatol 1985; 24:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/9\">",
"      Lin HY, Rocher LL, McQuillan MA, et al. Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989; 321:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/10\">",
"      Burack DA, Griffith BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med 1992; 92:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/11\">",
"      Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/12\">",
"      Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002; 40:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/13\">",
"      Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63:3136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/14\">",
"      Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/15\">",
"      Choi H. Epidemiology of crystal arthropathy. Rheum Dis Clin North Am 2006; 32:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/16\">",
"      Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/17\">",
"      Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007; 3:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/18\">",
"      O'Duffy JD, Hunder GG, Kelly PJ. Decreasing prevalence of tophaceous gout. Mayo Clin Proc 1975; 50:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/19\">",
"      Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout. Ann Rheum Dis 1997; 56:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/20\">",
"      Schlesinger N, Baker DG, Schumacher HR Jr. Serum urate during bouts of acute gouty arthritis. J Rheumatol 1997; 24:2265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/21\">",
"      Park YB, Park YS, Lee SC, et al. Clinical analysis of gouty patients with normouricaemia at diagnosis. Ann Rheum Dis 2003; 62:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/22\">",
"      Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol 2009; 36:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/23\">",
"      Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/24\">",
"      Joosten LA, Netea MG, Mylona E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1&beta; production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010; 62:3237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/25\">",
"      Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 52:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/26\">",
"      Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/27\">",
"      Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum 2007; 56:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/28\">",
"      Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum 2007; 57:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/29\">",
"      Simkin PA. The pathogenesis of podagra. Ann Intern Med 1977; 86:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/30\">",
"      McCarty DJ. Gout without hyperuricemia. JAMA 1994; 271:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/31\">",
"      Simkin PA, Campbell PM, Larson EB. Gout in Heberden's nodes. Arthritis Rheum 1983; 26:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/32\">",
"      Lally EV, Zimmermann B, Ho G Jr, Kaplan SR. Urate-mediated inflammation in nodal osteoarthritis: clinical and roentgenographic correlations. Arthritis Rheum 1989; 32:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/33\">",
"      Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/34\">",
"      Chen LX, Schumacher HR. Current trends in crystal identification. Curr Opin Rheumatol 2006; 18:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/35\">",
"      Pascual E. Gout update: from lab to the clinic and back. Curr Opin Rheumatol 2000; 12:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/36\">",
"      Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol 2009; 15:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/37\">",
"      Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/38\">",
"      Janssens HJ, Fransen J, van de Lisdonk EH, et al. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 2010; 170:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/39\">",
"      Choi HK, Al-Arfaj AM, Eftekhari A, et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis 2009; 68:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/40\">",
"      Nicolaou S, Yong-Hing CJ, Galea-Soler S, et al. Dual-energy CT as a potential new diagnostic tool in the management of gout in the acute setting. AJR Am J Roentgenol 2010; 194:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/41\">",
"      Glazebrook KN, Guimar&atilde;es LS, Murthy NS, et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology 2011; 261:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/42\">",
"      Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheumatology (Oxford) 2007; 46:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/43\">",
"      Rettenbacher T, Ennemoser S, Weirich H, et al. Diagnostic imaging of gout: comparison of high-resolution US versus conventional X-ray. Eur Radiol 2008; 18:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/44\">",
"      Filippucci E, Riveros MG, Georgescu D, et al. Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study. Osteoarthritis Cartilage 2009; 17:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/45\">",
"      De Miguel E, Puig JG, Castillo C, et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis 2012; 71:157.",
"     </a>",
"    </li>",
"    <li>",
"     Dalbeth N, Haskard DO. Pathophysiology of crystal-induced arthritis. In: Crystal-induced Arthropathies, Wortmann RL, Schumacher HR Jr, Becker MA, Ryan LM (Eds), Taylor &amp; Francis, New York 2006. p.239.",
"    </li>",
"    <li>",
"     McCarty DJ. Synovial fluid. In: Arthritis and Allied Conditions, 14th Edition, Koopman WJ (Ed), Lippincott Williams and Wilkins, Philadelphia 2001. p.83.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/48\">",
"      Schumacher HR, Smolyo AP, Tse RL, Maurer K. Arthritis associated with apatite crystals. Ann Intern Med 1977; 87:411.",
"     </a>",
"    </li>",
"    <li>",
"     Gutman AB. Gout and gouty arthritis. In: Textbook of Medicine, Beeson PB, McDermott W (Eds), Saunders, Philadelphia 1958. p.595.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/50\">",
"      Becker MA, Jolly M. Hyperuricemia and associated diseases. Rheum Dis Clin North Am 2006; 32:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/51\">",
"      Rousseau I, Cardinal E E, Raymond-Tremblay D, et al. Gout: radiographic findings mimicking infection. Skeletal Radiol 2001; 30:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/52\">",
"      Hsu CY, Shih TT, Huang KM, et al. Tophaceous gout of the spine: MR imaging features. Clin Radiol 2002; 57:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/53\">",
"      Schumacher HR Jr, Becker MA, Edwards NL, et al. Magnetic resonance imaging in the quantitative assessment of gouty tophi. Int J Clin Pract 2006; 60:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/54\">",
"      Gutman AB. The past four decades of progress in the knowledge of gout, with an assessment of the present status. Arthritis Rheum 1973; 16:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/55\">",
"      Hollingworth P, Scott JT, Burry HC. Nonarticular gout: hyperuricemia and tophus formation without gouty arthritis. Arthritis Rheum 1983; 26:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/56\">",
"      Wernick R, Winkler C, Campbell S. Tophi as the initial manifestation of gout. Report of six cases and review of the literature. Arch Intern Med 1992; 152:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/57\">",
"      Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/58\">",
"      Berger L, Y&uuml; TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 1975; 59:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/59\">",
"      TALBOTT JH, TERPLAN KL. The kidney in gout. Medicine (Baltimore) 1960; 39:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/60\">",
"      Batuman V, Maesaka JK, Haddad B, et al. The role of lead in gout nephropathy. N Engl J Med 1981; 304:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/61\">",
"      Craswell PW, Price J, Boyle PD, et al. Chronic renal failure with gout: a marker of chronic lead poisoning. Kidney Int 1984; 26:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/62\">",
"      Beck LH. Requiem for gouty nephropathy. Kidney Int 1986; 30:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/63\">",
"      Pascual E. The diagnosis of gout and CPPD crystal arthropathy. Br J Rheumatol 1996; 35:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/64\">",
"      Pascual E, Batlle-Gualda E, Mart&iacute;nez A, et al. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999; 131:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/65\">",
"      Agudelo CA, Weinberger A, Schumacher HR, et al. Definitive diagnosis of gout by identification of urate crystals in asymptomatic metatarsophalangeal joints. Arthritis Rheum 1979; 22:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/66\">",
"      Rege J, Shet T, Naik L. Fine needle aspiration of tophi for crystal identification in problematic cases of gout. A report of two cases. Acta Cytol 2000; 44:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/49/4890/abstract/67\">",
"      Shidham V, Chivukula M, Basir Z, Shidham G. Evaluation of crystals in formalin-fixed, paraffin-embedded tissue sections for the differential diagnosis of pseudogout, gout, and tumoral calcinosis. Mod Pathol 2001; 14:806.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1667 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4890=[""].join("\n");
var outline_f4_49_4890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H111564623\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ACUTE GOUTY ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Typical attack",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute polyarticular gout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis of acute gout",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Polarizing microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Criteria for clinical diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Resolution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3404322\">",
"      Differential diagnosis of acute gouty arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INTERCRITICAL GOUT AND RECURRENT GOUTY ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CHRONIC TOPHACEOUS GOUT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Clinical appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RENAL COMPLICATIONS OF CHRONIC HYPERURICEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Chronic urate nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DIAGNOSIS OF INTERCRITICAL OR CHRONIC TOPHACEOUS GOUT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Histologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Criteria for clinical diagnosis of intercritical gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111564623\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1667\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1667|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/42/35503\" title=\"diagnostic image 1\">",
"      Ultrasound of gouty arthritis of the metacarpophalangeal joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/61/31710\" title=\"diagnostic image 2\">",
"      Gout of the foot x ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1667|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/21/2387\" title=\"picture 1A\">",
"      MSU crystals in acute gout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/63/1023\" title=\"picture 1B\">",
"      CPPD crystal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/35/6708\" title=\"picture 1C\">",
"      Cholesterol crystal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/56/37775\" title=\"picture 2\">",
"      Tophus of the knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/60/26575\" title=\"picture 3\">",
"      Inflamed tophaceous gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1667|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/49/5916\" title=\"table 1\">",
"      Secondary uricemia production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/14/44267\" title=\"table 2\">",
"      Secondary uricemia excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/0/35852\" title=\"table 3\">",
"      Gout versus psuedogout",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=related_link\">",
"      Diuretic-induced hyperuricemia and gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=related_link\">",
"      Evaluation of the adult with polyarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3303?source=related_link\">",
"      Hyperuricemia and gout in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28344?source=related_link\">",
"      Pathophysiology of gouty arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=related_link\">",
"      Patient information: Gout (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/3/11314?source=related_link\">",
"      Patient information: Gout (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=related_link\">",
"      Prevention of recurrent gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=related_link\">",
"      Treatment of acute gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24230?source=related_link\">",
"      Uric acid balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_49_4891="Pathogen distribution ABRS";
var content_f4_49_4891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distribution of pathogens in adult bacterial rhinosinusitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Pathogen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Incidence (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        S. pneumonia",
"       </em>",
"      </td>",
"      <td>",
"       41",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        H. influenza",
"       </em>",
"      </td>",
"      <td>",
"       35",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        M. catarrhalis",
"       </em>",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Staph. aureus",
"       </em>",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anaerobes",
"      </td>",
"      <td>",
"       7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Streptococcus",
"       </em>",
"       species",
"      </td>",
"      <td>",
"       7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Other",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4891=[""].join("\n");
var outline_f4_49_4891=null;
var title_f4_49_4892="Recommendations for evacuation of burn patients from theater";
var content_f4_49_4892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for evacuation of burn patients from theater",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Burn severity*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evacuation recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Limited partial thickness burns not involving hands, joint, face, perineum",
"       </td>",
"       <td>",
"        Air evacuation to Landstuhl for wound care with expected return to duty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <p>",
"         Limited, partial thickness involving hands, joint, face, perineum OR",
"        </p>",
"        <p>",
"         Any limited full-thickness burn",
"        </p>",
"       </td>",
"       <td>",
"        Air evacuation to Institute of Surgical Research (ISR) burn center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Moderate partial or full-thickness burns, patient stable",
"       </td>",
"       <td>",
"        Transfer to ISR via Critical Care Air Transport Team (CCATT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Severe partial or full-thickness burns and/or inhalation injury requiring intubation, patient stable",
"       </td>",
"       <td>",
"        Transfer to ISR using burn Special Medical Augmentation Response Team (SMART)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Severe partial or full-thickness burns, patient unstable for air evacuation to the US",
"       </td>",
"       <td>",
"        Transfer to European burn center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Vesicant casualties",
"       </td>",
"       <td>",
"        Air evacuation to ISR",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Burn severity definitions: limited, 10 percent total body surface area (TBSA); moderate, 10 percent to 30 percent TBSA; severe, &gt;30 percent TBSA.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: D'Avignon L, Saffle J, Chung K, Cancio L. Prevention and management of infections associated with burns in the combat casualty. J Trauma 2008; 64:S277. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4892=[""].join("\n");
var outline_f4_49_4892=null;
var title_f4_49_4893="Causes of CPP";
var content_f4_49_4893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with chronic pelvic pain in women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Gynecologic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endometriosis*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic pelvic inflammatory disease*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pelvic adhesions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pelvic congestion (pelvic varicosities)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adenomyosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ovarian remnant syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Residual ovary syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leiomyoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endosalpingiosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neoplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fallopian tubal prolapse (post-hysterectomy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tuberculous salpingitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Benign cystic mesothelioma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postoperative peritoneal cysts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Mental health issues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Somatization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Substance abuse",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Physical and sexual abuse",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Depression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sleep disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Urinary tract",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interstitial cystitis/painful bladder syndrome*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recurrent urinary tract infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Urethral diverticulum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic urethral syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neoplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiation cystitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Gastrointestinal tract",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Irritable bowel syndrome*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inflammatory bowel disease and other causes of colitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diverticular colitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic intermittent bowel obstruction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neoplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic constipation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Celiac disease (Sprue)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Musculoskeletal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pelvic floor myalgia*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myofascial pain (trigger points)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coccygodynia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Piriformis syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hernia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abnormal posture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fibromyalgia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peripartum pelvic pain syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Neurologic disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neuralgia, especially of the iliohypogastric, ilioinguinal, genitofemoral, or pudendal nerves*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Herniated nucleus pulposus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neoplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neuropathic pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abdominal epilepsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abdominal migraine",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These diagnoses are the most common causes of CPP and backed by substantial evidence.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4893=[""].join("\n");
var outline_f4_49_4893=null;
var title_f4_49_4894="Exercise EF survival CHD";
var content_f4_49_4894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The exercise ejection fraction predicts survival in coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 249px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 908 patients with coronary heart disease who underwent rest and exercise radionuclide angiography and were followed for an average of 4.6 years, the exercise ejection fraction (EF) predicted total cardiac death as well as total cardiac events during each year of followup; patients with an EF 50 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Johnson, SH, Bigelow, C, Lee, KL, et al. Am J Cardiol 1991; 67:919.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4894=[""].join("\n");
var outline_f4_49_4894=null;
var title_f4_49_4895="SCJ GEJ coincide";
var content_f4_49_4895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnosis of Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cartoon depicting the appearance when the squamocolumnar and gastroesophageal junctions coincide. In this situation, there is no apparent columnar-lined esophagus (ie, the entire esophagus is lined by squamous epithelium).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology1999;117:218-28.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_49_4895=[""].join("\n");
var outline_f4_49_4895=null;
